Drug Abuse Warning Network (DAWN), 1994: [United States]

United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Office of Applied Studies

Codebook

Terms of Use

The terms of use for this study can be found at:

TABLE OF CONTENTS

1994 Drug Abuse Warning Network (DAWN)

Public Use File User Documentation

Rashna Ghadialy
Javier Porras
Hee-Choon Shin
Ellen Kaplowitz
Kenneth A. Rasinski

NORC, at the University of Chicago

June 16, 1999
Revised: August 24, 1999

ACKNOWLEDGMENTS

I. INTRODUCTION

The Drug Abuse Warning Network (DAWN) is the primary source of statistical information on the use of the emergency departments in the United States for the treatment of drug-related health problems. DAWN is an ongoing national probability survey conducted annually by the Substance Abuse and Mental Health Services Administration (SAMHSA) which produces estimates of drug-related emergency department visits for various substances.

The DAWN 1994 data file contains information collected from hospital emergency departments (ED's) across the country to monitor emergency medical problems associated with illicit, prescription, or over-the-counter drug use. The data are collected quarterly, and semiannual and annual reports are produced by the Office of Applied Statistics (OAS), a branch of the Substance Abuse and Mental Health Services Administration (SAMHSA) which is a division of the Department of Health and Human Services (DHSS). One of the uses of the data is to identify and track trends in emergency room visits due to use of illegal substances as they enter and spread through the United States.[1]

II. DESCRIPTION OF DAWN

The DAWN includes an annual national probability survey of drug-related problems treated in hospital emergency departments (EDs) and drug-related death data collected from a nonrandom sample of medical examiners and coroners' offices (ME/Cs). Since 1972, DAWN has been a source of data on drug-induced or drug-related emergency department visits and medical examiner or coroner deaths. This surveillance system is managed by the Office of Applied Studies, a component of the Substance Abuse and Mental Health Services Administration (SAMHSA) and the U.S. Department of Health and Human Services. More than 500 EDs provide data for DAWN. They are part of a scientifically selected sample of general hospitals in the country. The DAWN sample is constructed to produce estimates of substance abuse visits to emergency departments across the Nation and to 21 metropolitan areas. The sample design of DAWN does not permit state-level estimates.

Information on drug-related and drug-induced deaths, involving both legal and illegal drugs, is collected from ME/Cs representing 175 jurisdictions. ED and ME/C data are collected and reported from the following metropolitan areas: Atlanta, GA; Boston, MA; Buffalo, NY; Chicago, IL; Dallas, TX; Denver, CO; Detroit, MI; Los Angeles, CA; Miami, FL; Minneapolis, MN; New Orleans, LA: New York, NY; Newark, NJ; Philadelphia, PA; Phoenix, AZ; San Diego, CA; San Francisco, CA; Seattle, WA; and Washington, D.C. ED data also are reported from hospitals in Baltimore, MD and ME/C data are reported by ME/Cs in Kansas City, KS/MO.

---

[1]Material for this codebook was drawn from SAMHSA reports related to DAWN, including: SAMHSA Statistical Series, Annual Emergency Department Data 1994. Data from the Drug Abuse Warning Network (DAWN)." Series I, Number 14-A. (October 1996).

DAWN reports include detailed data summaries for each metropolitan area and show the distribution of drug abuse episodes by demographic characteristics, number of episodes, and drug group and the distribution of drug mentions by reason for emergency department contact, classified by drug group. DAWN also reports the number of mentions per 100,000 population for certain drugs on a semiannual basis by metropolitan area, so it is possible to see if the rates of mentions are going up or down and to compare the metropolitan area rates with the national rates.

Data from DAWN can be used to identify substances associated with drug abuse episodes reported by DAWN-affiliated facilities; to monitor drug abuse patterns and trends and detect new abuse entities and new combinations; to assess health hazards associated with drug abuse; and to provide data for national, state, and local drug abuse policy and program planning.

DAWN has several advantages in that it is ongoing and, thus, continually provides current and consistent information; it identifies specific drugs being used and it provides data for selected metropolitan areas as well as a composite national picture.

DAWN collects information on drug abuse-related medical examiner cases and on all patients treated in an ED because of problems caused by or related to drug abuse. In general, drug abuse-related cases must meet three criteria to be reported to DAWN: (1) the use of prescription drugs in a manner inconsistent with accepted medical practice; (2) the use of over-the-counter (OTC) drugs contrary to approved labeling; (3) the use of any other substance (heroin, marijuana, peyote, glue, aerosols, etc.) for psychic effect, dependence, or suicide; the use of alcohol alone is not reported.

III. DATA COLLECTION METHODOLOGY

Since the early 1970's, DAWN has collected information on patients seeking hospital emergency department treatment related to their use of an illegal drug or the non-medical use of a legal drug. The survey provides data that describe the impact of drug use on hospital emergency departments in the United States. Data are collected by trained reporters (nurses and other hospital personnel) who review medical charts for indications--noted by hospital staff who treated the patients--that drug use was the reason for the emergency department visit. Thus, the accuracy of these reports depends on the careful recording of this information by hospital staff.

To be included in DAWN, the person presenting to the emergency department (i.e., the patient) must be aged 6 years and older and meet all four of the following criteria:

1. the patient was treated in the hospital's emergency department;

2. the patient's presenting problem(s) was induced by or related to drug use, regardless of when the drug ingestion occurred;

3. the case involved the nonmedical use of a legal drug or any use of an illegal drug;

4. the patient's reason for taking the substance(s) included one of the following: (1) dependence, (2) suicide attempt or gesture, or (3) psychic effects.

DAWN excludes cases involving alcohol as the sole substance of abuse. Information is presented on the characteristics of decedents by gender, race/ethnicity, age, and manner of death, along with this information by type of drugs mentioned.

Hospitals eligible for the DAWN study are non-Federal, short-stay general hospitals that have a 24-hour emergency department. Since 1988, the DAWN emergency department data have been collected from a representative sample of these hospitals located throughout the coterminous United States, including 21 oversampled metropolitan areas. The data from this sample are used to generate estimates of the total number of emergency department drug episodes and drug mentions in all such hospitals. A methodology was developed for generating comparable estimates for the years 1978 through 1987, taking advantage of historical data available on the characteristics of the universe of eligible hospitals and the extensive data files of drug-related episodes compiled over the years by DAWN. These estimates are useful in providing a context for the analysis of recent trends in drug-related emergency department episodes.

Approximately 13,000 drug abuse episodes are processed monthly through DAWN. Data accuracy is ensured through a combination of quality assurance activities. For example, adherence to DAWN reporting guidelines is monitored through periodic record reviews and reabstracting studies. Particular emphasis is placed on training and on continuing support and followup provided by the field liaisons and central office data monitors.

Within each facility participating in DAWN, a designated reporter, usually a member of the emergency department or medical records staff, is responsible for identifying drug-related episodes and recording and submitting data on each case. An episode report is submitted for each patient visiting a DAWN emergency department whose presenting problem(s) was related to their own drug use. In each facility (hospital ED or medical examiner's office) that participates in DAWN, the reporter is assigned to data collection activities. Ideally, an ED nurse (or other medical personnel) reviews all ED records daily and completes a one-page DAWN form on each drug abuse-related case. This report records basic patient demographic data and detailed substance abuse information. When ED staff are not available, other service departments (such as social services, medical records, pharmacy, poison control, volunteer departments) may be recruited to participate in the reporting process. In some cases, the hospital may designate an independent reporter (i.e., not a hospital staff person) to report DAWN data. The DAWN staff are bound by Federal laws protecting patient confidentiality. The data collection form does not include any patient identifying information.

DAWN reporters submit completed forms, along with weekly log sheets listing case totals, to SAMHSA's DAWN operations contractor. Each participating facility or its designee (e.g., the reporter, nurses' fund) receives a small honorarium for submitting data. The DAWN operations contractor assumes responsibility for the other costs incurred in reporting, such as mailing reports, training facility personnel, telephone communication between facility reporters, and the contractor staff who review DAWN reports. Contractor staff review, verify, and compile DAWN data. They are supported by regional field liaison staff who travel to facilities to provide training, evaluation, and problem-solving as needed.

Each report of a drug-related emergency department episode includes demographic information about the patient and the circumstances surrounding the episode. Up to four different substances, in addition to alcohol-in-combination, can be specified for each episode. Alcohol and legal drugs are included only when they are reported as used in combination with illegal drugs. The data are then weighted to produce national and metropolitan area estimates of emergency department drug-related episodes.

A drug episode is defined as an emergency department visit that was directly related to the use of an illegal drug or the non-medical use of a legal drug for persons aged 6 years and older. The number of emergency department episodes reported in DAWN is not synonymous with the number of individuals involved. One person may make repeated visits to an emergency department or to several emergency departments, thus producing a number of episodes. As no patient identifiers are collected, it is impossible to determine the number of individuals involved in the reported episodes.

A drug mention refers to a substance that was mentioned during a drug-related emergency department episode. In addition to alcohol-in-combination, up to four substances may be reported for each drug-related episode; thus, the total number of mentions exceeds the number of total episodes. Much of the time there is only one drug mentioned one during an episode In these cases "episode" and "mention" are synonymous. It should be noted that a particular drug mention may or may not be the confirmed "cause" of the episode when multiple drugs have been mentioned. Even when only one substance is reported for an episode, allowance should still be made for reportable drugs not mentioned or for other contributory factors. To reduce the size of the data file and to make the data more accessible to users, the DAWN Public Use File (PUF) presents data at the episode level. Total and unique numbers of mentions are included for each episode.

IV.   SAMPLE DESIGN

When DAWN was begun in the early 1970's, a random sample of hospital emergency departments was chosen for inclusion. Over the ensuing years, a number of facilities were lost from the original sample due to closure, merger, or voluntary termination and the sample was not updated in such a way as to maintain randomness. Therefore, attrition and nonrandom replacement led to a sample that was no longer representative of all hospital emergency departments in the coterminous United States.

In the 1980's, the DAWN sample was redesigned and a new sample was drawn. The American Hospital Association (AHA) 1984 and 1985 Annual Surveys of Hospitals were used to obtain a sampling frame. Non-Federal, short-stay hospitals with a 24-hour emergency department were eligible for DAWN. Hospitals in the frame were stratified according to size, with hospitals reporting 80,000 or more annual emergency department visits assigned to a single stratum and selected with certainty. Additional strata were defined according to whether the hospital had an organized outpatient department or a chemical/alcohol inpatient unit. Twenty-one Metropolitan Statistical Areas (MSAs) were designated for oversampling. In five of the metropolitan areas all eligible hospitals were assigned to a National Panel and sampled. In addition to the other strata, hospitals in the metropolitan areas were classified as to whether they were inside or outside a central city.

Sample implementation began in 1986 and by 1988 hospital recruitment progressed to the point where national and metropolitan area [the 21 MSAs/Primary Metropolitan Statistical Areas (PMSAs)] estimates could be made with reasonable precision. The estimation procedure for the new probability sample was modified in 1989 and included the use of an estimator with adjustments for two types of nonresponse and a ratio adjustment (or benchmark adjustment) based on ancillary data from the AHA. A sample maintenance procedure was developed to randomly select "newly eligible" hospitals from the AHA each year using the same selection probabilities as the new sample. This procedure will allow the sample to be kept up-to-date and representative of over 5,000 DAWN-eligible hospitals in the coterminous U.S.

V.   WEIGHTS AND PRECISION OF ESTIMATES

DAWN weights are generated each quarter for each hospital in the sample and are the product of a four component model that considers (1) the base sampling weight calculated as the reciprocal of the sampling probability; (2) an adjustment for atypical reporting, applicable to certain hospitals that merge, split, or respond in an unusual way; (3) an adjustment for nonresponse based either on complete nonparticipation or failure to provide data on all the reporting days in a given time period; and (4) a benchmark factor, applied within metropolitan areas, that adjusts the total number of emergency department visits among participating sample hospitals to the total for the population of hospitals as determined from the sampling frame.

Each estimate from the DAWN emergency department sample data is subject to sampling variability, which is the variation of the estimate that would be observed if different samples were drawn from the same population using the same procedures. The sampling variability of an estimate is measured by its standard error (SE) and relative standard error (RSE), which is defined as the standard error expressed as a percentage of the value of the estimate. The precision of an estimate is inversely related to the degree of sampling variability as measured by the RSE; the greater the RSE value, the lower the precision.

VI.   STANDARD ERROR CALCULATIONS AND DESIGN EFFECTS

The DAWN sample design is complex in a way that effects the calculation of standard errors of estimates. For reports published by SAMHSA custom software was written to produce exact sample-design standard errors that are published in the various DAWN reports. This section reports on deviations from the exact standard errors that may result from the construction of the PUF and the disclosure modifications. The DAWN sample design includes stratification and clustering. Two stratification variables (STRATA and DAWNAREA) have been included on the PUF for use in estimation and standard error calculation. The DAWN sample design also includes hospital (HOSPID) as a clustering component. An additional component of variance is the covariancd of estimates across quarters.

The Design Effect (DEFF; see Kish, 1965) statistic is the ratio of the standard error calculated from a reduced design, such as the simple random sample assumption made by SAS and SPSS or any other design that does not fully capture all of the sources of error variation due to the design, to the exact standard error, which takes into account all of the design-related variance components. Tables 1, 2 and 3 show the DEFF's for a number of published DAWN totals assuming a simple random sample.

The DEFFs for the simple random sample weighted totals were calculated as follows: (1) the number of episodes and mentions for each hospital were counted; each hospital for each quarter was counted as a separate entity. Hospitals that were split or merged for disclosure purposes were counted in their split or merged condition, that is, one split or merged unit was counted as one hospital. (2) the weight variable was normalized to the number of hospitals in each MSA. The normalization was conducted by dividing each case weight by the mean weight in each MSA. When this is done, the sum of the weights is equal to the unweigted sample size. Standard errors of the sample *means* were calculated after the weights were normalized. These standard errors were multiplied by the number of total hospitals in the population (estimated by the sum of the non-normalized weights in each MSA) to obtain the standard errors for the totals.

VII.   SUGGESTIONS FOR CALCULATING STATISTICAL TESTS USING THE DAWN DATA

It is advised that any analysis of the DAWN PUF use weights and take into account design effects. Perhaps the simplest way to analyze the DAWN data is to use statistical software such as SAS or SPSS or another package that assumes a simple random sample in its statistical calculations to calculate weighted estimates and standard errors. When using this method design effects can be easily taken into account through the following procedure: (1) create a new weight by dividing the case weight by the average weight for the analytic group of interests (e.g., the entire sample, MSAs, or subgroups) times the most appropriate design effect from Tables 1 and 2. The significance levels for the statistics that result from this procedure will approximate the exact significance levels to take into consideration nonindependence (or clustering) of cases. In cases where the drug or drug by MSA design effect is not appropriate, an average design effect can be used. Alternatively, the square root of DEFF (called DEFT by Kish, 1965) can be used as a multiplier of the standard error from the reduced design to give an approximation of what the standard error would be if the full sample design were taken into account.

Table 1

Examples of estimates and standard errors for total episodes, total mentions,
and mentions of selected drug groups: 1994

Total episodes, total mentions, and drug group	Estimated episodes	Standard errors	PUF94 estimates	SRS Standard errors	DEFF
Episodes	518,521	28,000	518,521	25587	1.19750
Mentions	900,317	48,617	900,140	44918	1.17151
Acetaminophen	38,674	2,359	38,666	2381	0.98133
Alcohol-in-combination	160,744	10,127	160,730	8455	1.43449
Alprazolam	17,183	1,839	17,183	1420	1.67776
Amitriptyline	11,297	1,209	11,293	1104	1.20001
Amitriptyline combinations	616	188	616	172	1.19162
Amphetamine	9,664	2,271	9,651	1364	2.77301
Aspririn	19,358	1,549	19,349	1430	1.17276
Chloral hydrate	480	154	480	160	0.92838
Chlordiazepoxide	2,695	582	2,693	437	1.76972
Chlorpromazine	2,614	387	2,615	353	1.20467
Chlorazepate	718	189	717	182	1.07781
Cocaine	142,878	14,431	142,809	9524	2.29611
Codeine	2,147	333	2,147	337	0.97538
Codeine combinations	7,378	907	7,376	752	1.45616
d-Propoxyphene	7,478	703	7,473	706	0.99126
Desipramine	1,246	260	1,246	232	1.25086
Diazepam	13,568	1,398	13,570	1167	1.43609
Diphenhydramine	9,537	896	9,536	845	1.12449
Doxepin	4,268	632	4,267	572	1.22139
Ethchlorvynol	89	12	89	15	0.64183
Flurazepam	1,495	281	1,493	241	1.36112
Glutethimide	11	6	11	7	0.80980
Haloperidol	3,072	424	3,073	377	1.26430
Heroin/Morphine	64,013	5,761	64,133	4158	1.91965
Hydromorphone	896	332	894	254	1.70685
Imipramine	2,764	401	2,766	380	1.11079
Inhalants/Solvents/Aerosols	1,637	308	1,637	264	1.36439
Lorazepam	12,248	1,862	12,250	1381	1.81793
LSD	5,150	994	5,153	857	1.34491
Marijuana/Hashish	40,183	3,657	40,142	2677	1.86592
Meperidine HCL	736	163	735	152	1.14421
Meprobamate	437	142	437	150	0.89942
Methadone	3,234	401	3,234	346	1.33960
Methamphetamine/Speed	17,665	4,946	17,674	2965	2.78227
Methaqualone	610	205	610	179	1.31751
Methylphenidate	1,191	217	1,190	220	0.97335
O.T.C. diet aids	1,905	324	1,905	316	1.04831
O.T.C. sleep aids	6,890	861	6,892	706	1.48913
Oxycodone	4,084	662	4,084	504	1.72345
PCP/PCP combinations	6,019	626	6,010	533	1.38130
Pentazocine	294	111	293	115	0.92783
Pentobarbital	170	88	170	90	0.95434
Phenobarbital	2,471	356	2,473	345	1.06277
Secobarbital	212	89	212	91	0.96332
Secobarbital/Amobarbital	10	2	10	4	0.28526
Thioridazine	3,190	501	3,192	454	1.21719
Trifluoperazine	1,395	292	1,396	269	1.17855

Table 2

Standard errors and design effects for total drug abuse episodes, total drug mentions, and mentions of cocaine

according to metropolitan area 1994, and assuming a simple random sample and weighted estimates

Metropolitan Area	Total Episodes				Total Mentions				Cocaine Mentions			
	Estimate	SE	SRS SE	SRS DEFF	Estimate	SE	SRS SE	SRS DEFF	Estimate	SE	SRS SE	SRS DEFF
Total coterminous U.S.	518,521	28,000	25587	1.20	900,317	48,617	44,918	1.17	142,878	14,431	9,524	2.30
Atlanta	10,828	1,570	810	3.76	21,362	3,204	1,511	4.50	6,165	851	392	4.72
Baltimore	15,862	1,126	1728	0.42	26,897	2,044	3,188	0.41	8,882	826	1,309	0.40
Boston	15,225	2,055	1507	1.86	28,231	4,178	3,043	1.89	4,715	646	509	1.61
Buffalo	2,926	138	792	0.03	5,069	243	1,463	0.03	1,207	86	323	0.07
Chicago	21,511	1,549	1488	1.08	37,273	2,646	2,468	1.15	10,797	1,080	1,028	1.10
Dallas	5,160	361	423	0.73	9,360	655	779	0.71	1,246	140	135	1.06
Denver	5,034	795	830	0.92	8,417	1,229	1,272	0.93	1,299	257	260	0.98
Detroit	17,162	3,209	3477	0.85	31,748	6,381	6,662	0.92	7,964	2,254	2,332	0.93
Los Angeles-Long Beach	19,256	2,041	1217	2.81	33,221	5,149	2,932	3.08	5,070	730	446	2.69
Miami-Hialeah	5,849	351	156	5.07	9,383	563	254	4.90	2,742	222	116	3.68
Minneapolis-St.Paul	4,611	618	601	1.06	9,030	1,490	1,257	1.40	578	62	92	0.46
New Orleans	4,739	242	248	0.95	9,459	473	511	0.86	1,884	143	123	1.36
New York	43,127	6,771	4884	1.92	64,199	9,630	7,270	1.75	20,214	3,962	2,848	1.94
Newark	9,395	1,954	1628	1.44	16,529	3,736	3,001	1.55	4,288	1,136	899	1.60
Philadelphia	17,711	1,948	1635	1.42	31,717	3,489	2,960	1.39	8,446	1,343	1,017	1.74
Phoenix	6,879	248	728	0.12	11,563	370	1,185	0.10	1,064	71	129	0.30
San Diego	5,051	525	620	0.72	8,701	818	1,015	0.65	668	162	147	1.22
San Francisco	11,766	435	943	0.21	17,576	685	1,417	0.23	3,123	147	291	0.25
Seattle	10,049	2,040	2825	0.52	17,173	3,538	4,880	0.53	2,896	788	1,058	0.55
St. Louis	6,039	1,310	1013	1.67	11,021	2,700	1,985	1.85	2,329	689	520	1.76
Washington, D.C.	14,152	2,038	2048	0.99	25,222	4,363	4,233	1.06	4,849	824	860	0.92
National Panel	266,189	26,353	20245	1.69	468,167	46,349	35,607	1.69	42,330	13,334	7,988	2.79

Table 3

Standard errors and design effects for mentions of cocaine, heroine/morphine, and
marijuana/hashish, according to metropolitan area 1994,
and assuming a simple random sample and weighted estimates

Metropolitan Area	Heroin/Morphine Mentions				Marijuana/Hashish mentions			
	Estimate	SE	SRS SE	SRS DEFF	Estimate	SE	SRS SE	SRS DEFF
Total coterminous U.S.	64,013	5,761	4158	1.92	40,183	3,657	2,677	1.87
Atlanta	456	70	40	3.01	1,527	224	103	4.78
Baltimore	7,510	661	1015	0.42	770	22	131	0.03
Boston	2,527	334	270	1.53	1,870	393	356	1.22
Buffalo	355	21	99	0.04	230	11	55	0.04
Chicago	4,787	641	557	1.33	2,219	226	226	1.00
Dallas	237	45	33	1.87	477	126	61	4.24
Denver	495	129	132	0.95	406	42	70	0.37
Detroit	2,106	537	532	1.02	2,849	832	723	1.32
Los Angeles-Long Beach	2,949	301	202	2.22	1,658	424	215	3.88
Miami-Hialeah	264	9	21	0.19	711	47	41	1.33
Minneapolis-St.Paul	78	6	18	0.10	482	208	107	3.79
New Orleans	197	31	21	2.16	885	39	66	0.35
New York	11,185	2,628	2041	1.66	2,589	373	301	1.54
Newark	4,498	1,525	1019	2.24	628	196	161	1.48
Philadelphia	2,440	349	336	1.08	2,085	323	279	1.34
Phoenix	483	21	59	0.12	453	144	95	2.28
San Diego	695	167	155	1.17	513	116	91	1.64
San Francisco	3,555	174	321	0.30	479	35	67	0.28
Seattle	2,092	542	710	0.58	870	197	274	0.52
St. Louis	408	91	95	0.92	901	423	288	2.16
Washington, D.C.	1,261	158	173	0.83	2,712	906	741	1.49
National Panel	15,437	4,708	2808	2.81	14,868	3,345	2,220	2.27

VIII.   NONSAMPLING ERROR

When producing estimates from any sample survey, two types of errors are possible--sampling and nonsampling errors. The sampling error of an estimate is the error caused by the selection of a sample instead of a census of hospitals. Sampling error is reduced by selecting a large sample or by using efficient sample design and estimation strategies such as stratification, optimal allocation, and ratio estimation. Nonsampling errors occur from nonresponse, difficulties in the interpretation of the collection form, coding errors, computer processing errors, errors in the sampling frame, reporting errors, and other errors. Many procedures are in place to minimize nonsampling errors such as data editing and periodic retraining of data collectors. Further, nonrespondents are identified for additional recruitment. Late reporters are assigned for priority data collection and respondents with changes in reporting are designated for followup.

Because data are abstracted from medical records completed by hospital staff who treated the patients, the accuracy of these reports depends on their careful recording of these conditions. In the DAWN technical report it is noted that methods for identifying patient drug abuse can differ from hospital to hospital. The DAWN has recently received criticism for underrepresenting drug abuse episodes that are associated with major trauma, such as motor vehicle accidents and violent assault (Brookoff, Campbell, and Shaw, 1993). Such underrepresentation may be because trauma patients may not be in a position to give a history of drug abuse while being treated in the emergency department. (See Swisher, 1984, for an extensive critique of the original DAWN design and data).

It is also important to recognize that DAWN does not provide a complete picture of problems associated with drug use, but rather focuses on the impact that these problems have on hospital emergency departments in the United States . If a person is admitted to another part of the hospital for treatment, treated in a physician's office or at a drug treatment center, the episode would not be included in DAWN.

IX..   PROTECTION OF HOSPITALS AND PATIENTS AGAINST DISCLOSURE IN THE PUF

It is the intention of SAMHSA to make the DAWN data available to the public through this DAWN 1994 public release file. However, in doing so it is important to maintain the confidentiality of individuals represented in the substance-related emergency records, and of the identities of the hospital. This is especially important because the data are of a very sensitive nature, containing information about illicit drug use and motivation for such use. It is also important because participating hospitals were given assurance of the confidentiality of the information provided. Therefore a disclosure analysis of the DAWN data was conducted resulting in protective modifications to the PUF data.

Certain procedures were applied to the DAWN data to guard against direct or indirect disclosure of event or emergency department identity. These procedures include eliminating obvious identifiers, such as names and publicly available identification numbers. The reason for these eliminations are obvious, and conform to most social science data sets publicly available, whether they are produced by the government or by other research institutions.

11

In addition, the procedures included masking tasks applied to both hospitals and events. The general point of the masking procedure is to disguise the identity of hospitals or events. One type of masking procedure involved dividing some large hospitals into smaller pieces and mixing the pieces with other hospitals comparable in size to the pieces. In another masking procedure, small hospitals were joined with larger ones. At the event-level, key identifying variables were selected and crosstabulated to find any cells with two or fewer events. Data in these cells were modified to eliminate the small cells and make inferential disclosure of any hospital or event practically impossible. **Data have been masked to exceed a confusability criterion based on a multivariable assessment of demographic characteristics associated with events. All of these procedures make it extremely difficult to attempt the identify specific hospitals or events.**

The disclosure analyses work and creation of the public use data file was done by the National Opinion Research Center (NORC) at the University of Chicago under contract to SAMHSA. The PUF contains the 1994 DAWN data. Twenty-one Metropolitan Statistical Areas and a National Panel are represented in the data. The Metropolitan Statistical Areas are Atlanta, Baltimore, Boston, Buffalo, Chicago, Dallas, Denver, Detroit, LA-Long Beach, Miami-Hialeah, Minneapolis-St. Paul, New Orleans, New York, Newark, Philadelphia, Phoenix, St. Louis, San Diego, San Francisco, Seattle, and Washington, DC. The National Panel is a national probability sample of hospitals without PMSA designations. Because no geographic indicators (i.e., PMSAs) are attached to the hospitals in the National Panel, disclosure analysis was not necessary.

In order to create a PUF from the original (restricted use) file, several steps were taken to ensure that individual client records could not be identified. First, the variable that could clearly identify treatment units was deleted (e.g. AHA ID). Second, variables determined to be of significant disclosure risk ("key" variables) were collapsed and/or recoded (e.g., AGE, RACE, and SEX). Some larger hospitals were split into pseudo-hospitals and mixed in with smaller hospitals. (Please note that HOSPID is the cluster variable that is needed when calculating standard errors using special software, such as SUDAAN, that takes into account the complex sample design. See Section VI for more detail). Analysis of the unique records in the file was done. Unique records were considered to be those in which the patterns of responses to the "key" variables were shared by fewer than three records. For these records, the key variables were ranked in order of importance and data were suppressed until there were no remaining unique records. As Table 4 indicates, about 0.54 percent of the records in the full file were identified as unique. Of these unique records, an average of 1.36 data values per record were suppressed.

There are two statistical considerations resulting from the disclosure analysis that must be addressed. The first concerns bias in the estimates. Data suppression will cause a downward bias in estimates of drug mentions. The bias is very small for the overall sample and slightly larger for estimates based on key variable subgroups. Thus, estimates of drug mentions from the PUF will be slightly lower than published estimates. NORC designed procedures to spread the bias across groups represented in the key variables. Because of the hospital joining/splitting, weights were altered for some hospitals. The goal of the joining/splitting procedure was to maintain total episode estimates. Again, the bias was minimal, as quarterly estimates by DAWNAREA were preserved in this procedure.

The second consideration concerns standard errors of estimates. These will be slightly different than reported results due to the joining or splitting of hospitals. NORC's procedures were designed to minimize the effect on standard error. Analysis indicates that the reweightings and suppression will have very little effect on the file's analytic utility.

TABLE 4: Results of the Disclosure Procedures

Number of Records	165,646
% Unique Records	0.54%
Mean number of data values suppressed among small cells	1.36
Percent data suppressed with respect to entire dataset	0.19%
Range of difference scores for percent distributions before and after data suppression	0.0% - 0.1%

All frequencies in the PUF Codebook (Appendix 2) are unweighted.

The procedures to protect against disclosure come with some cost. First, it will not be possible to conduct hospital-level analyses, either within or across the four quarters of the 1994 data, using the DAWN public release data. Only aggregate analysis within or across Primary Metropolitan Statistical Areas (PMSAs) are permitted. Second, estimates derived from the PUF will not always match those published in SAMHSA reports, because the drug estimates for the demographic cells are slightly biased due to event-level data suppression and weight adjustments. Although the bias can be in either direction, if present, it is likely to be slightly downward because the suppression of a sparse number of age, race and sex data removed cases from demographic cells by setting their value on one or more demographic variables to missing.

Nonetheless, the DAWN PUF is rich in the type of research opportunities it provides. The file will allow researchers to learn about abuse of any of the 52 categories of drugs, alone or in combination, for the entire country and by metropolitan area (using the DAWNAREA variable). With the DAWN PUF a researcher would be able to tell which drugs are most and least likely to be used in combination, and whether this varies by region, demographic group, region by group, and motive for drug use. In addition, it is possible to examine drug type and route of administration by various status variables, such as age category, gender, race/ethnicity category, both across the nation and within metropolitan areas. The information in DAWN can be used to examine which drugs and routes most associated with recreational use, addiction, or psychoactive effects, overall, by metropolitan area, and within demographic subgroups result in an emergency department visit.

The DAWN PUF can answer other important questions. For example, what drugs, combinations of drugs, or routes of administration are most associated with death? What are the characteristics of individuals, both in terms of drug use, route of administration, and demographics who are admitted to the hospital. What factors are associated with those who refuse treatment. Which drugs or drug combinations are most associated with treatment seeking, overdosing, or having unpredictable reactions? Do these vary by area and demographic subgroup? These issues and more can be addressed using the DAWN PUF.

Extensive efforts were made to assure that the bias in estimates introduced by disclosure-required suppression was distributed equally among subgroups in which suppression occurred. In the few cases where the bias for a demographic cell estimate is greater than 50 episodes, the average relative bias, is only around 1% because of the large number of episodes. This PUF is designed for use with data analysis programs that calculate standard errors of complex sample designs. The masking, hospital splitting, and joining have only a small effect on the standard errors.

X. USER RESPONSIBILITY

Users are reminded that the data are to be used solely for statistical analysis and reporting of aggregated information and not for investigation of specific individuals or organizations.

XI. DAWN PUBLIC USE FILE LIST OF VARIABLES

The DAWN PUF contains the following variables:

AGE: Specifies the age group of the patient at the time of the emergency department visit.

DAWNAREA: Indicates the Primary Metropolitan Statistical Area (PMSA) code. According to the U.S. Bureau of the Census, if an area that qualifies as a Metropolitan Area (MA) has more than one million persons, PMSAs may be defined within it. PMSAs consist of a large urbanized county or cluster of counties that demonstrates very strong internal economic social links, in addition to close ties to other portions of the larger area. When PMSAs are established, the larger area of which they are component parts is designated a consolidated metropolitan statistical area (CMSA).

DAWNQTR: Indicates the quarter of the year of the ED visit.

DAY: Specifies the day of the week of the ED visit.

DISPOSTN: Indicates the patient disposition, i.e., whether the patient was released from the hospital, admitted, left against advice, or died.

DRUG01 through DRUG52: Indicates each drug or drug category mentioned. These consist of the 50 drug categories most frequently mentioned, plus "All other drugs" and "Drug unknown" and are the same that are listed in Table 3.01 (Number of emergency department drug mentions by selected drug category according to age, race/ethnicity, and gender: 1994), in the report "SAMHSA Statistical Series, Annual Emergency Department Data 1994. Data from the Drug Abuse Warning Network (DAWN)." Series I, Number 14-A. (October 1996), page 55.

FORM01 through FORM52: Indicates the form of each drug or drug category mentioned.

FWEIGHT: Indicates the weight of the episode after disclosure.

HOSPID: This is the pseudo identification number assigned to each hospital.

MOTIVE: Specifies the patient's motive for taking the drug, e.g., dependence, recreational use, suicide, etc.

RACE: Identifies the patient's race/ethnicity.

REASON: Indicates the reason for the emergency department visit, for example, unexpected drug reaction, overdose, withdrawal, etc.

ROUTE01 through ROUTE52: Identifies the route of drug administration (Oral, injected, sniff/snorted, missing, no response, multiple response) for each drug or drug category mentioned.

SEX: Indicates whether the patient is male or female.

STRATUM: Specifies the first stage sampling unit.

TOTMENS: The total number of drugs mentioned in the episode (with duplicates)

UNIQMENS: The unique number of drugs mentioned in the episode (without duplicates)

CASEID: Specifies the case identification number assigned to the ED visit

YEAR: Indicates the year in which the episode occurred, always 1994.

For four drug categories: DRUG15 (codeine combinations), DRUG30 (inhalant/solvent/aerosol), DRUG51 (other drugs), and DRUG52 (drugs unknown), when the drug category was mentioned more than once and different forms and/or routes were given corresponding to each mention, form and/or route is coded "multiple response". If the same form and/or route was given for each of the multiple mentions, that form and/or route is coded.

XII.   REFERENCES

Brookoff, D; Campbell, E. A; Shaw, L. M. (1993). The underreporting of cocaine-related trauma: Drug abuse warning network reports vs hospital toxicology tests. *American Journal of Public Health*. Vol 83*(3)*, 369-371.

Drug Abuse Warning Network Sample Design and Estimation Procedures: Technical Report. DHHS Publication No. (SMA)98-3178; Printed November 1997. (BKD249)

Kish, L. (1965). *Survey sampling*. New York: John Wiley and Sons.

XIII.   OTHER DAWN PUBLICATIONS

SAMHSA Statistical Series, Annual Emergency Department Data 1994. Data from the Drug Abuse Warning Network (DAWN)." Series I, Number 14-A. (October 1996).

Historical Estimates from the Drug Abuse Warning Network - Advance Report #16: *1978-1994 Estimates of Drug-Related Emergency Department Episodes.* DHHS Publication No. (SMA)96-3105; SAMHSA; Printed August 1996. Also available on the Internet World Wide Web. (AR016)

Annual Medical Examiner Data 1993 - Data from the Drug Abuse Warning Network. Series 1, Number 13-B; DHHS Publication No. (SMA) 95-3019; SAMHSA; Printed 1995. (BKD160)

Preliminary Estimates from the Drug Abuse Warning Network - Advance Report #8: *1993 Preliminary Estimates of Drug-Related Emergency Department Episodes*. SAMHSA; Printed December 1994. Also available on the Internet World Wide Web. (AR008)

Preliminary Estimates from the Drug Abuse Warning Network - Advance Report #6: *1993 Preliminary Estimates of Drug-Related Emergency Room Episodes* (January - June 1993). SAMHSA, Printed March 1994. (1988 through 1993 data). (AR006)

Annual Emergency Room Data 1992 - Data from the Drug Abuse Warning Network. Series 1, Number 12-A, DHHS Publication No. (SMA)94-2080; SAMHSA; Printed 1994. (BKD141)

Annual Medical Examiner Data 1992 - Data from the Drug Abuse Warning Network. Series 1, Number 12-B; DHHS Publication No. (SMA)94-2081; SAMHSA; Printed 1994. (BKD20)

Estimates from the Drug Abuse Warning Network - Advance Report #4: *1992 Estimates of Drug-Related Emergency Room Episodes*. SAMHSA; Printed September 1993. (AR004)

Annual Emergency Room Data 1991 - Data from the Drug Abuse Warning Network. Series 1, Number 11-A; DHHS Publication No. (ADM)92-1955; ADAMHA; Printed 1992 (BKD90).

Annual Medical Examiner Data 1991 - Data from the Drug Abuse Warning Network. Series 1, Number 11-B; DHHS Publication No. (ADM)92-1955; ADAMHA; Printed 1992. (BKD91)

XIIV. JOURNAL ARTICLES BASED ON DAWN DATA

Adams, E. H. (1991). Prevalence of prescription drug abuse: Data from the National Institute on Drug Abuse. *New York State Journal of Medicine*. Vol 91*(11, Suppl)*, 32-36.

Albeck, J. H. (1987). Withdrawal and detoxification from benzodiazepine dependence: A potential role for clonazepam. *Journal of Clinical Psychiatry*. Vol 48 (*Suppl*), 44-48.

Colliver, J. (1991). Characteristics and Implications of the New DAWN Emergency Room Sample. *CEWG,* 403-423 (in RP0909)

Davis, H.; Baum, C.; Graham, D. J. (1991). Indices of drug misuse for prescription drugs. *International Journal of the Addictions*. Vol 26*(7)*, 777-795.

Domingo-Salvany, A.; Perez, K.; Hartnoll, R. L, Orti, R. M. (1994). The underreporting of drug-related episodes in a Barcelona emergency room. *American Journal of Public Health*. Vol 84*(8)*, 1340.

Goode, E. (1990). The American drug panic of the 1980s: Social construction or objective threat? *The International Journal of the Addictions*, Vol 25, *(9)*, 1083-1098.

Jaffe, J. H. (1977) Some reflections on the evolution of current American approaches to problems of drug abuse and to the treatment of drug abusers. *Journal of Drug Issues*. Vol 7(*1*), 1-12.

Kopstein, A. (1992). Drug Abuse Related Emergency Room Episodes in the United States. *British Journal of Addictions*, 87; 1071-1075, (1989/1990 data).

Pottieger, A. E; Tressell, P. A; Inciardi, J. A; Rosales, T. A. (1992) Cocaine use patterns and overdose. *Journal of Psychoactive Drugs.* Vol 24*(4)*, 399-410.

Ryser, P. E. (1983). Sex differences in substance abuse: 1976-1979. *International Journal of the Addictions*. Vol 18*(1)*, 71-87.

Swisher, J. D; Hu, T. (1984). A review of the reliability and validity of the Drug Abuse Warning Network. *International Journal of the Addictions.* Vol 19(*1*), 57-77.

Wolf, R. C; Case, P; Pagano, M. (1998). Estimation of the prevalence of injection drug use in greater Boston in 1993. *Journal of Psychoactive Drugs*. Vol 30*(1)*, 21-24.

Woodward, J. A.; Retka, R. L; Ng, L. (1984). Construct validity of heroin abuse estimators. *International Journal of the Addictions*. Vol 19(*1*), 93-117.

APPENDIX 1 DAWN 1994 PUBLIC USE FILE RECORD LAYOUT

Order	Variable	Type	Length	Position	Format	Label
13	AGE	Num	4	59	AGE.	AGE OF PATIENT
1	CASEID	Num	8	0		Unique identifier for each episode
12	DAWNAREA	Num	4	55	DAWNAREA.	NEW SAMPLE PMSA CODE
7	DAWNQTR	Num	4	28	DAWNQTR.	ABSOLUTE QUARTER NUMBER IN DAWN
172	DAY	Num	3	539	DAYS.	Day of the week
5	DISPOSTN	Num	4	20	DISPOSTN.	PATIENT DISPOSITION
16	DRUG01	Num	3	71	DRUG1A.	ACETAMINOPHEN
17	DRUG02	Num	3	74	DRUG2A.	ALCOHOL-IN-COMBO
18	DRUG03	Num	3	77	DRUG3A.	ALPRAZOLAM
19	DRUG04	Num	3	80	DRUG4A.	AMITRIPTYLINE
20	DRUG05	Num	3	83	DRUG5A.	AMITRIPTYLN COMB
21	DRUG06	Num	3	86	DRUG6A.	AMPHETAMINE
22	DRUG07	Num	3	89	DRUG7A.	ASPIRIN
23	DRUG08	Num	3	92	DRUG8A.	BUTALBITAL COMBO
24	DRUG09	Num	3	95	DRUG9A.	CHLORAL HYDRATE
25	DRUG10	Num	3	98	DRUG10A.	CHLORDIAZEPOXIDE
26	DRUG11	Num	3	101	DRUG11A.	CHLORPROMAZINE
27	DRUG12	Num	3	104	DRUG12A.	CLORAZEPATE
28	DRUG13	Num	3	107	DRUG13A.	COCAINE
29	DRUG14	Num	3	110	DRUG14A.	CODEINE
30	DRUG15	Num	3	113	DRUG15A.	CODEINE COMBO
31	DRUG16	Num	3	116	DRUG16A.	d-PROPOXYPHENE
32	DRUG17	Num	3	119	DRUG17A.	DESIPRAMINE
33	DRUG18	Num	3	122	DRUG18A.	DIAZEPAM
34	DRUG19	Num	3	125	DRUG19A.	DIPHENHYDRAMINE
35	DRUG20	Num	3	128	DRUG20A.	DIPHENYLHYDANTOIN SODIUM
36	DRUG21	Num	3	131	DRUG21A.	DOXEPIN
37	DRUG22	Num	3	134	DRUG22A.	ETHCHLORVYNOL
38	DRUG23	Num	3	137	DRUG23A.	FLUOXETINE
39	DRUG24	Num	3	140	DRUG24A.	FLURAZEPAM
40	DRUG25	Num	3	143	DRUG25A.	GLUTETHIMIDE
41	DRUG26	Num	3	146	DRUG26A.	HALOPERIDOL
42	DRUG27	Num	3	149	DRUG27A.	HEROIN/MORPHINE
43	DRUG28	Num	3	152	DRUG28A.	HYDROMORPHONE
44	DRUG29	Num	3	155	DRUG29A.	IMIPRAMINE
45	DRUG30	Num	3	158	DRUG30A.	INHLNT/SOL/AER
46	DRUG31	Num	3	161	DRUG31A.	LORAZEPAM
47	DRUG32	Num	3	164	DRUG32A.	LSD
48	DRUG33	Num	3	167	DRUG33A.	MARIJUANA/HASHISH
49	DRUG34	Num	3	170	DRUG34A.	MEPERIDINE HCL
50	DRUG35	Num	3	173	DRUG35A.	MEPROBAMATE
51	DRUG36	Num	3	176	DRUG36A.	METHADONE
52	DRUG37	Num	3	179	DRUG37A.	METHAMPHETAMINE
53	DRUG38	Num	3	182	DRUG38A.	METHAQUALONE
54	DRUG39	Num	3	185	DRUG39A.	METHYLPHENIDATE
55	DRUG40	Num	3	188	DRUG40A.	OTC DIET AIDS
56	DRUG41	Num	3	191	DRUG41A.	OTC SLEEP AIDS

Order	Variable	Type	Length	Position	Format	Label
57	DRUG42	Num	3	194	DRUG42A.	OXYCODONE
58	DRUG43	Num	3	197	DRUG43A.	PCP/PCP COMBO
59	DRUG44	Num	3	200	DRUG44A.	PENTAZOCINE
60	DRUG45	Num	3	203	DRUG45A.	PENTOBARBITAL
61	DRUG46	Num	3	206	DRUG46A.	PHENOBARBITAL
62	DRUG47	Num	3	209	DRUG47A.	SECOBARBITAL
63	DRUG48	Num	3	212	DRUG48A.	SECOBARBTL/AMOBARBITAL
64	DRUG49	Num	3	215	DRUG49A.	THIORIDAZINE
65	DRUG50	Num	3	218	DRUG50A.	TRIFLUOPERAZINE
66	DRUG51	Num	3	221	DRUG51A.	DRUGS, OTH CAT
67	DRUG52	Num	3	224	DRUG52A.	DRUGS, UNKNOWN
68	FORM01	Num	3	227	FORM.	Form of ACETAMINOPHEN
69	FORM02	Num	3	230	FORM.	Form of ALCOHOL-IN-COMBO
70	FORM03	Num	3	233	FORM.	Form of ALPRAZOLAM
71	FORM04	Num	3	236	FORM.	Form of AMITRIPTYLINE
72	FORM05	Num	3	239	FORM.	Form of AMITRIPTYLN COMB
73	FORM06	Num	3	242	FORM.	Form of AMPHETAMINE
74	FORM07	Num	3	245	FORM.	Form of ASPIRIN
75	FORM08	Num	3	248	FORM.	Form of BUTALBITAL COMBO
76	FORM09	Num	3	251	FORM.	Form of CHLORAL HYDRATE
77	FORM10	Num	3	254	FORM.	Form of CHLORDIAZEPOXIDE
78	FORM11	Num	3	257	FORM.	Form of CHLORPROMAZINE
79	FORM12	Num	3	260	FORM.	Form of CLORAZEPATE
80	FORM13	Num	3	263	FORM.	Form of COCAINE
81	FORM14	Num	3	266	FORM.	Form of CODEINE
82	FORM15	Num	3	269	FORM.	Form of CODEINE COMBO
83	FORM16	Num	3	272	FORM.	Form of d-PROPOXYPHENE
84	FORM17	Num	3	275	FORM.	Form of DESIPRAMINE
85	FORM18	Num	3	278	FORM.	Form of DIAZEPAM
86	FORM19	Num	3	281	FORM.	Form of DIPHENHYDRAMINE
87	FORM20	Num	3	284	FORM.	Form of DIPHENYLHYDANTOIN SODIUM
88	FORM21	Num	3	287	FORM.	Form of DOXEPIN
89	FORM22	Num	3	290	FORM.	Form of ETHCHLORVYNOL
90	FORM23	Num	3	293	FORM.	Form of FLUOXETINE
91	FORM24	Num	3	296	FORM.	Form of FLURAZEPAM
92	FORM25	Num	3	299	FORM.	Form of GLUTETHIMIDE
93	FORM26	Num	3	302	FORM.	Form of HALOPERIDOL
94	FORM27	Num	3	305	FORM.	Form of HEROIN/MORPHINE
95	FORM28	Num	3	308	FORM.	Form of HYDROMORPHONE
96	FORM29	Num	3	311	FORM.	Form of IMIPRAMINE
97	FORM30	Num	3	314	FORM.	Form of INHLNT/SOL/AER
98	FORM31	Num	3	317	FORM.	Form of LORAZEPAM
99	FORM32	Num	3	320	FORM.	Form of LSD
100	FORM33	Num	3	323	FORM.	Form of MARIJUANA/HASHISH
101	FORM34	Num	3	326	FORM.	Form of MEPERIDINE HCL
102	FORM35	Num	3	329	FORM.	Form of MEPROBAMATE
103	FORM36	Num	3	332	FORM.	Form of METHADONE
104	FORM37	Num	3	335	FORM.	Form of METHAMPHETAMINE

Order	Variable	Type	Length	Position	Format	Label
105	FORM38	Num	3	338	FORM.	Form of METHAQUALONE
106	FORM39	Num	3	341	FORM.	Form of METHYLPHENIDATE
107	FORM40	Num	3	344	FORM.	Form of OTC DIET AIDS
108	FORM41	Num	3	347	FORM.	Form of OTC SLEEP AIDS
109	FORM42	Num	3	350	FORM.	Form of OXYCODONE
110	FORM43	Num	3	353	FORM.	Form of PCP/PCP COMBO
111	FORM44	Num	3	356	FORM.	Form of PENTAZOCINE
112	FORM45	Num	3	359	FORM.	Form of PENTOBARBITAL
113	FORM46	Num	3	362	FORM.	Form of PHENOBARBITAL
114	FORM47	Num	3	365	FORM.	Form of SECOBARBITAL
115	FORM48	Num	3	368	FORM.	Form of SECOBARBTL/AMOBARBITAL
116	FORM49	Num	3	371	FORM.	Form of THIORIDAZINE
117	FORM50	Num	3	374	FORM.	Form of TRIFLUOPERAZINE
118	FORM51	Num	3	377	FORM.	Form of DRUGS in OTH CAT
119	FORM52	Num	3	380	FORM.	Form of DRUGS, UNKNOWN
11	FWEIGHT	Num	8	47		Episode weight
10	HOSPID	Num	8	39		Unique identifier for each hospital
3	MOTIVE	Num	4	12	MOTIVE.	DRUG USE MOTIVE
14	RACE	Num	4	63	RACE.	PATIENT RACE/ETHNICITY
4	REASON	Num	4	16	REASON.	REASON FOR ER VISIT
120	ROUTE01	Num	3	383	ROUTE.	Route for ACETAMINOPHEN
121	ROUTE02	Num	3	386	ROUTE.	Route for ALCOHOL-IN-COMBO
122	ROUTE03	Num	3	389	ROUTE.	Route for ALPRAZOLAM
123	ROUTE04	Num	3	392	ROUTE.	Route for AMITRIPTYLINE
124	ROUTE05	Num	3	395	ROUTE.	Route for AMITRIPTYLN COMB
125	ROUTE06	Num	3	398	ROUTE.	Route for AMPHETAMINE
126	ROUTE07	Num	3	401	ROUTE.	Route for ASPIRIN
127	ROUTE08	Num	3	404	ROUTE.	Route for BUTALBITAL COMBO
128	ROUTE09	Num	3	407	ROUTE.	Route for CHLORAL HYDRATE
129	ROUTE10	Num	3	410	ROUTE.	Route for CHLORDIAZEPOXIDE
130	ROUTE11	Num	3	413	ROUTE.	Route for CHLORPROMAZINE
131	ROUTE12	Num	3	416	ROUTE.	Route for CLORAZEPATE
132	ROUTE13	Num	3	419	ROUTE.	Route for COCAINE
133	ROUTE14	Num	3	422	ROUTE.	Route for CODEINE
134	ROUTE15	Num	3	425	ROUTE.	Route for CODEINE COMBO
135	ROUTE16	Num	3	428	ROUTE.	Route for d-PROPOXYPHENE
136	ROUTE17	Num	3	431	ROUTE.	Route for DESIPRAMINE
137	ROUTE18	Num	3	434	ROUTE.	Route for DIAZEPAM
138	ROUTE19	Num	3	437	ROUTE.	Route for DIPHENHYDRAMINE
139	ROUTE20	Num	3	440	ROUTE.	Route for DIPHENYLHYDANTOIN SODIUM
140	ROUTE21	Num	3	443	ROUTE.	Route for DOXEPIN
141	ROUTE22	Num	3	446	ROUTE.	Route for ETHCHLORVYNOL
142	ROUTE23	Num	3	449	ROUTE.	Route for FLUOXETINE
143	ROUTE24	Num	3	452	ROUTE.	Route for FLURAZEPAM
144	ROUTE25	Num	3	455	ROUTE.	Route for GLUTETHIMIDE
145	ROUTE26	Num	3	458	ROUTE.	Route for HALOPERIDOL
146	ROUTE27	Num	3	461	ROUTE.	Route for HEROIN/MORPHINE
147	ROUTE28	Num	3	464	ROUTE.	Route for HYDROMORPHONE

Order	Variable	Type	Length	Position	Format	Label
148	ROUTE29	Num	3	467	ROUTE.	Route for IMIPRAMINE
149	ROUTE30	Num	3	470	ROUTE.	Route for INHLNT/SOL/AER
150	ROUTE31	Num	3	473	ROUTE.	Route for LORAZEPAM
151	ROUTE32	Num	3	476	ROUTE.	Route for LSD
152	ROUTE33	Num	3	479	ROUTE.	Route for MARIJUANA/HASHISH
153	ROUTE34	Num	3	482	ROUTE.	Route for MEPERIDINE HCL
154	ROUTE35	Num	3	485	ROUTE.	Route for MEPROBAMATE
155	ROUTE36	Num	3	488	ROUTE.	Route for METHADONE
156	ROUTE37	Num	3	491	ROUTE.	Route for METHAMPHETAMINE
157	ROUTE38	Num	3	494	ROUTE.	Route for METHAQUALONE
158	ROUTE39	Num	3	497	ROUTE.	Route for METHYLPHENIDATE
159	ROUTE40	Num	3	500	ROUTE.	Route for OTC DIET AIDS
160	ROUTE41	Num	3	503	ROUTE.	Route for OTC SLEEP AIDS
161	ROUTE42	Num	3	506	ROUTE.	Route for OXYCODONE
162	ROUTE43	Num	3	509	ROUTE.	Route for PCP/PCP COMBO
163	ROUTE44	Num	3	512	ROUTE.	Route for PENTAZOCINE
164	ROUTE45	Num	3	515	ROUTE.	Route for PENTOBARBITAL
165	ROUTE46	Num	3	518	ROUTE.	Route for PHENOBARBITAL
166	ROUTE47	Num	3	521	ROUTE.	Route for SECOBARBITAL
167	ROUTE48	Num	3	524	ROUTE.	Route for SECOBARBTL/AMOBARBITAL
168	ROUTE49	Num	3	527	ROUTE.	Route for THIORIDAZINE
169	ROUTE50	Num	3	530	ROUTE.	Route for TRIFLUOPERAZINE
170	ROUTE51	Num	3	533	ROUTE.	Route for DRUGS in OTH CAT
171	ROUTE52	Num	3	536	ROUTE.	Route for DRUGS, UNKNOWN
15	SEX	Num	4	67	SEX.	SEX OF PATIENT
9	STRATUM	Num	3	36		Modified stratum
6	TOTMENS	Num	4	24		TOTAL MENTIONS IN EPISODE (W/ DUPS)
8	UNIQMENS	Num	4	32		UNIQUE MENTIONS IN EPISODE (S/ DUPS)
2	YEAR	Num	4	8		YEAR EPISODE OCCURRED

APPENDIX 2 DAWN 1994 PUBLIC USE FILE CODEBOOK

AGE OF PATIENT

AGE	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-1=MISSING	646	0.4	646	0.4
1= 6 <=AGE<= 11	185	0.1	831	0.5
2=12 <=AGE<= 17	10327	6.2	11158	6.7
3=18 <=AGE<= 20	9351	5.6	20509	12.4
4=21 <=AGE<= 25	20287	12.2	40796	24.6
5=26 <=AGE<= 29	21825	13.2	62621	37.8
6=30 <=AGE<= 34	33001	19.9	95622	57.7
7=35 <=AGE<= 44	51177	30.9	146799	88.6
8=45 <=AGE<= 54	14695	8.9	161494	97.5
9=55 AND OVER	4152	2.5	165646	100.0

NEW SAMPLE PMSA CODE

DAWNAREA	Frequency	Percent	Cumulative Frequency	Cumulative Percent
1=ATLANTA	7464	4.5	7464	4.5
2=BALTIMORE	14349	8.7	21813	13.2
3=BOSTON	7064	4.3	28877	17.4
4=BUFFALO	2311	1.4	31188	18.8
5=CHICAGO	11587	7.0	42775	25.8
6=DALLAS	3314	2.0	46089	27.8
7=DENVER	3838	2.3	49927	30.1
8=DETROIT	10378	6.3	60305	36.4
9=LA-LONG BEACH	10107	6.1	70412	42.5
10=MIAMI-HIALEAH	5464	3.3	75876	45.8
11=MINNEAPOLIS-ST PAUL	3448	2.1	79324	47.9
12=NEW ORLEANS	3692	2.2	83016	50.1
13=NEW YORK	22847	13.8	105863	63.9
14=NEWARK	5867	3.5	111730	67.5
15=PHILADELPHIA	10803	6.5	122533	74.0
16=PHOENIX	5311	3.2	127844	77.2
17=ST. LOUIS	4033	2.4	131877	79.6
18=SAN DIEGO	3785	2.3	135662	81.9
19=SAN FRANCISCO	8016	4.8	143678	86.7
20=SEATTLE	5118	3.1	148796	89.8
21=WASHINGTON, DC	8640	5.2	157436	95.0
22=NATIONAL PANEL	8210	5.0	165646	100.0

ABSOLUTE QUARTER NUMBER IN DAWN

DAWNQTR	Frequency	Percent	Cumulative Frequency	Cumulative Percent
1=FIRST QUARTER	39458	23.8	39458	23.8
2=SECOND QUARTER	41348	25.0	80806	48.8
3=THIRD QUARTER	42857	25.9	123663	74.7
4=FOURTH QUARTER	41983	25.3	165646	100.0

DAY OF THE WEEK

DAY	Frequency	Percent	Cumulative Frequency	Cumulative Percent
1=SUNDAY	23032	13.9	23032	13.9
2=MONDAY	23584	14.2	46616	28.1
3=TUESDAY	23940	14.5	70556	42.6
4=WEDNESDAY	23770	14.3	94326	56.9
5=THURSDAY	23331	14.1	117657	71.0
6=FRIDAY	23507	14.2	141164	85.2
7=SATURDAY	24482	14.8	165646	100.0

PATIENT DISPOSITION

DISPOSTN	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-1=MISSING	1338	0.8	1338	0.8
1=TREATED, RELEASE	93099	56.2	94437	57.0
2=ADMITTED	66810	40.3	161247	97.3
3=LEFT AGNST ADVIC	4119	2.5	165366	99.8
4=DIED	280	0.2	165646	100.0

ACETAMINOPHEN

DRUG01	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use ACETAMINOPHEN	158168	95.5	158168	95.5
1=Used ACETAMINOPHEN	7478	4.5	165646	100.0

ALCOHOL-IN-COMBO

DRUG02	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use ALCOHOL-IN-COMBO	107568	64.9	107568	64.9
1=Used ALCOHOL-IN-COMBO	58078	35.1	165646	100.0

ALPRAZOLAM

DRUG03	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use ALPRAZOLAM	162602	98.2	162602	98.2
1=Used ALPRAZOLAM	3044	1.8	165646	100.0

AMITRIPTYLINE

DRUG04	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use AMITRIPTYLINE	164012	99.0	164012	99.0
1=Used AMITRIPTYLINE	1634	1.0	165646	100.0

AMITRIPTYLN COMB

DRUG05	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use AMITRIPTYLN COMB	165550	99.9	165550	99.9
1=Used AMITRIPTYLN COMB	96	0.1	165646	100.0

AMPHETAMINE

DRUG06	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use AMPHETAMINE	163354	98.6	163354	98.6
1=Used AMPHETAMINE	2292	1.4	165646	100.0

ASPIRIN

DRUG07	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use ASPIRIN	161957	97.8	161957	97.8
1=Used ASPIRIN	3689	2.2	165646	100.0

BUTALBITAL COMBO

DRUG08	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use BUTALBITAL COMBO	165314	99.8	165314	99.8
1=Used BUTALBITAL COMBO	332	0.2	165646	100.0

CHLORAL HYDRATE

DRUG09	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use CHLORAL HYDRATE	165546	99.9	165546	99.9
1=Used CHLORAL HYDRATE	100	0.1	165646	100.0

CHLORDIAZEPOXIDE

DRUG10	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use CHLORDIAZEPOXIDE	165188	99.7	165188	99.7
1=Used CHLORDIAZEPOXIDE	458	0.3	165646	100.0

CHLORPROMAZINE

DRUG11	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use CHLORPROMAZINE	165155	99.7	165155	99.7
1=Used CHLORPROMAZINE	491	0.3	165646	100.0

CLORAZEPATE

DRUG12	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use CLORAZEPATE	165480	99.9	165480	99.9
1=Used CLORAZEPATE	166	0.1	165646	100.0

COCAINE

DRUG13	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use COCAINE	96760	58.4	96760	58.4
1=Used COCAINE	68886	41.6	165646	100.0

CODEINE

DRUG14	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use CODEINE	165192	99.7	165192	99.7
1=Used CODEINE	454	0.3	165646	100.0

CODEINE COMBO

DRUG15	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use CODEINE COMBO	164213	99.1	164213	99.1
1=Used 1 CODEINE COMBO	1430	0.9	165643	100.0
2=Used 2 CODEINE COMBO	3	0.0	165646	100.0

d-PROPOXYPHENE

DRUG16	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use d-PROPOXYPHENE	164564	99.3	164564	99.3
1=Used d-PROPOXYPHENE	1082	0.7	165646	100.0

DESIPRAMINE

DRUG17	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use DESIPRAMINE	165424	99.9	165424	99.9
1=Used DESIPRAMINE	222	0.1	165646	100.0

DIAZEPAM

DRUG18	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use DIAZEPAM	162538	98.1	162538	98.1
1=Used DIAZEPAM	3108	1.9	165646	100.0

DIPHENHYDRAMINE

DRUG19	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use DIPHENHYDRAMINE	163642	98.8	163642	98.8
1=Used DIPHENHYDRAMINE	2004	1.2	165646	100.0

DIPHENYLHYDANTOIN SODIUM

DRUG20	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use DIPHENYLHYDANTOIN SODIUM	164708	99.4	164708	99.4
1=Used DIPHENYLHYDANTOIN SODIUM	938	0.6	165646	100.0

DOXEPIN

DRUG21	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use DOXEPIN	165025	99.6	165025	99.6
1=Used DOXEPIN	621	0.4	165646	100.0

ETHCHLORVYNOL

DRUG22	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use ETHCHLORVYNOL	165591	100.0	165591	100.0
1=Used ETHCHLORVYNOL	55	0.0	165646	100.0

FLUOXETINE

DRUG23	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use FLUOXETINE	163863	98.9	163863	98.9
1=Used FLUOXETINE	1783	1.1	165646	100.0

FLURAZEPAM

DRUG24	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use FLURAZEPAM	165334	99.8	165334	99.8
1=Used FLURAZEPAM	312	0.2	165646	100.0

GLUTETHIMIDE

DRUG25	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use GLUTETHIMIDE	165643	100.0	165643	100.0
1=Used GLUTETHIMIDE	3	0.0	165646	100.0

HALOPERIDOL

DRUG26	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use HALOPERIDOL	164722	99.4	164722	99.4
1=Used HALOPERIDOL	924	0.6	165646	100.0

HEROIN/MORPHINE

DRUG27	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use HEROIN/MORPHINE	132742	80.1	132742	80.1
1=Used HEROIN/MORPHINE	32904	19.9	165646	100.0

HYDROMORPHONE

DRUG28	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use HYDROMORPHONE	165525	99.9	165525	99.9
1=Used HYDROMORPHONE	121	0.1	165646	100.0

IMIPRAMINE

DRUG29	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use IMIPRAMINE	165229	99.7	165229	99.7
1=Used IMIPRAMINE	417	0.3	165646	100.0

INHALENT/SOLVENT/AEROSOL

DRUG30	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use INHLNT/SOLV/AERO	165298	99.8	165298	99.8
1=Used 1 INHLNT/SOLV/AERO	343	0.2	165641	100.0
2=Used 2 INHLNT/SOLV/AERO	5	0.0	165646	100.0

LORAZEPAM

DRUG31	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use LORAZEPAM	163939	99.0	163939	99.0
1=Used LORAZEPAM	1707	1.0	165646	100.0

LSD

DRUG32	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use LSD	164185	99.1	164185	99.1
1=Used LSD	1461	0.9	165646	100.0

MARIJUANA/HASHISH

DRUG33	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use MARIJUANA/HASHISH	149301	90.1	149301	90.1
1=Used MARIJUANA/HASHISH	16345	9.9	165646	100.0

MEPERIDINE HCL

DRUG34	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use MEPERIDINE HCL	165451	99.9	165451	99.9
1=Used MEPERIDINE HCL	195	0.1	165646	100.0

 MEPROBAMATE

DRUG35	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use MEPROBAMATE	165544	99.9	165544	99.9
1=Used MEPROBAMATE	102	0.1	165646	100.0

METHADONE

DRUG36	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use METHADONE	164066	99.0	164066	99.0
1=Used METHADONE	1580	1.0	165646	100.0

METHAMPHETAMINE

DRUG37	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use METHAMPHETAMINE	161787	97.7	161787	97.7
1=Used METHAMPHETAMINE	3859	2.3	165646	100.0

METHAQUALONE

DRUG38	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use METHAQUALONE	165530	99.9	165530	99.9
1=Used METHAQUALONE	116	0.1	165646	100.0

METHYLPHENIDATE

DRUG39	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use METHYLPHENIDATE	165438	99.9	165438	99.9
1=Used METHYLPHENIDATE	208	0.1	165646	100.0

OVER THE COUNTER DIET AIDS

DRUG40	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use OTC DIET AIDS	165373	99.8	165373	99.8
1=Used OTC DIET AIDS	273	0.2	165646	100.0

OVER THE COUNTER SLEEP AIDS

DRUG41	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use OTC SLEEP AIDS	164506	99.3	164506	99.3
1=Used OTC SLEEP AIDS	1140	0.7	165646	100.0

OXYCODONE

DRUG42	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use OXYCODONE	164760	99.5	164760	99.5
1=Used OXYCODONE	886	0.5	165646	100.0

PCP/PCP COMBO

DRUG43	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use PCP/PCP COMBO	162119	97.9	162119	97.9
1=Used PCP/PCP COMBO	3527	2.1	165646	100.0

PENTAZOCINE

DRUG44	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use PENTAZOCINE	165595	100.0	165595	100.0
1=Used PENTAZOCINE	51	0.0	165646	100.0

PENTOBARBITAL

DRUG45	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use PENTOBARBITAL	165623	100.0	165623	100.0
1=Used PENTOBARBITAL	23	0.0	165646	100.0

PHENOBARBITAL

DRUG46	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use PHENOBARBITAL	165016	99.6	165016	99.6
1=Used PHENOBARBITAL	630	0.4	165646	100.0

SECOBARBITAL

DRUG47	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use SECOBARBITAL	165597	100.0	165597	100.0
1=Used SECOBARBITAL	49	0.0	165646	100.0

SECOBARBTL/AMOBARBITAL

DRUG48	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use SECOBARBTL/AMOBARBITAL	165638	100.0	165638	100.0
1=Used SECOBARBTL/AMOBARBITAL	8	0.0	165646	100.0

THIORIDAZINE

DRUG49	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use THIORIDAZINE	165114	99.7	165114	99.7
1=Used THIORIDAZINE	532	0.3	165646	100.0

TRIFLUOPERAZINE

DRUG50	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use TRIFLUOPERAZINE	165451	99.9	165451	99.9
1=Used TRIFLUOPERAZINE	195	0.1	165646	100.0

DRUGS, OTHER CATEGORY

DRUG51	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use DRUG,OTHER CAT	131420	79.3	131420	79.3
1=Used 1 DRUG,OTHER CAT	26954	16.3	158374	95.6
2=Used 2 DRUGS, OTHER CAT	5809	3.5	164183	99.1
3=Used 3 DRUGS, OTHER CAT	1253	0.8	165436	99.9
4=Used 4 DRUGS, OTHER CAT	210	0.1	165646	100.0

DRUGS, UNKNOWN

DRUG52	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use DRUG, UNKNOWN	150566	90.9	150566	90.9
1=Used 1 DRUG, UNKNOWN	15077	9.1	165643	100.0
2=Used 2 DRUGS, UNKNOWN	3	0.0	165646	100.0

Form of ACETAMINOPHEN

FORM01	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	4	0.0	4	0.0
-2=NO RESPONSE	55	0.0	59	0.0
-1=MISSING	273	0.2	332	0.2
0=Did not use drug	158168	95.5	158500	95.7
1=TABL/CAP/PILL	7114	4.3	165614	100.0
2=AEROSOL	8	0.0	165622	100.0
3=LIQUID/ORAL	18	0.0	165640	100.0
4=POWDER	1	0.0	165641	100.0
6=LIQUID/INJECT	1	0.0	165642	100.0
8=PLANT MATERIAL	2	0.0	165644	100.0
11=PIECES/CHUNKS	2	0.0	165646	100.0

Form of ALCOHOL-IN-COMBO

FORM02	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use drug	107568	64.9	107568	64.9
3=LIQUID/ORAL	58078	35.1	165646	100.0

Form of ALPRAZOLAM

FORM03	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-2=NO RESPONSE	17	0.0	17	0.0
-1=MISSING	162	0.1	179	0.1
0=Did not use drug	162602	98.2	162781	98.3
1=TABL/CAP/PILL	2856	1.7	165637	100.0
2=AEROSOL	5	0.0	165642	100.0
3=LIQUID/ORAL	2	0.0	165644	100.0
4=POWDER	1	0.0	165645	100.0
11=PIECES/CHUNKS	1	0.0	165646	100.0

Form of AMITRIPTYLINE

FORM04	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	1	0.0	1	0.0
-2=NO RESPONSE	13	0.0	14	0.0
-1=MISSING	64	0.0	78	0.0
0=Did not use drug	164012	99.0	164090	99.1
1=TABL/CAP/PILL	1551	0.9	165641	100.0
2=AEROSOL	3	0.0	165644	100.0
4=POWDER	1	0.0	165645	100.0
8=PLANT MATERIAL	1	0.0	165646	100.0

Form of AMITRIPTYLN COMB

FORM05	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-2=NO RESPONSE	3	0.0	3	0.0
-1=MISSING	6	0.0	9	0.0
0=Did not use drug	165550	99.9	165559	99.9
1=TABL/CAP/PILL	87	0.1	165646	100.0

Form of AMPHETAMINE

FORM06	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	1	0.0	1	0.0
-2=NO RESPONSE	30	0.0	31	0.0
-1=MISSING	1278	0.8	1309	0.8
0=Did not use drug	163354	98.6	164663	99.4
1=TABL/CAP/PILL	580	0.4	165243	99.8
2=AEROSOL	1	0.0	165244	99.8
3=LIQUID/ORAL	3	0.0	165247	99.8
4=POWDER	301	0.2	165548	99.9
6=LIQUID/INJECT	69	0.0	165617	100.0
7=CIGARETTE	6	0.0	165623	100.0
8=PLANT MATERIAL	1	0.0	165624	100.0
10=OTHER	2	0.0	165626	100.0
11=PIECES/CHUNKS	20	0.0	165646	100.0

Form of ASPIRIN

FORM07	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	3	0.0	3	0.0
-2=NO RESPONSE	23	0.0	26	0.0
-1=MISSING	130	0.1	156	0.1
0=Did not use drug	161957	97.8	162113	97.9
1=TABL/CAP/PILL	3521	2.1	165634	100.0
2=AEROSOL	3	0.0	165637	100.0
3=LIQUID/ORAL	4	0.0	165641	100.0
4=POWDER	1	0.0	165642	100.0
5=PAPER	1	0.0	165643	100.0
10=OTHER	3	0.0	165646	100.0

Form of BUTALBITAL COMBO

FORM08	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	1	0.0	1	0.0
-2=NO RESPONSE	5	0.0	6	0.0
-1=MISSING	11	0.0	17	0.0
0=Did not use drug	165314	99.8	165331	99.8
1=TABL/CAP/PILL	313	0.2	165644	100.0
3=LIQUID/ORAL	2	0.0	165646	100.0

Form of CHLORAL HYDRATE

FORM09	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-2=NO RESPONSE	1	0.0	1	0.0
-1=MISSING	4	0.0	5	0.0
0=Did not use drug	165546	99.9	165551	99.9
1=TABL/CAP/PILL	91	0.1	165642	100.0
3=LIQUID/ORAL	4	0.0	165646	100.0

Form of CHLORDIAZEPOXIDE

FORM10	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	1	0.0	1	0.0
-2=NO RESPONSE	7	0.0	8	0.0
-1=MISSING	29	0.0	37	0.0
0=Did not use drug	165188	99.7	165225	99.7
1=TABL/CAP/PILL	420	0.3	165645	100.0
3=LIQUID/ORAL	1	0.0	165646	100.0

Form of CHLORPROMAZINE

FORM11	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-2=NO RESPONSE	5	0.0	5	0.0
-1=MISSING	20	0.0	25	0.0
0=Did not use drug	165155	99.7	165180	99.7
1=TABL/CAP/PILL	460	0.3	165640	100.0
3=LIQUID/ORAL	4	0.0	165644	100.0
4=POWDER	2	0.0	165646	100.0

Form of CLORAZEPATE

FORM12	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-2=NO RESPONSE	2	0.0	2	0.0
-1=MISSING	11	0.0	13	0.0
0=Did not use drug	165480	99.9	165493	99.9
1=TABL/CAP/PILL	153	0.1	165646	100.0

Form of COCAINE

FORM13	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	1157	0.7	1157	0.7
-2=NO RESPONSE	286	0.2	1443	0.9
-1=MISSING	33422	20.2	34865	21.0
0=Did not use drug	96760	58.4	131625	79.5
1=TABL/CAP/PILL	74	0.0	131699	79.5
2=AEROSOL	8	0.0	131707	79.5
3=LIQUID/ORAL	38	0.0	131745	79.5
4=POWDER	14122	8.5	145867	88.1
5=PAPER	59	0.0	145926	88.1
6=LIQUID/INJECT	1845	1.1	147771	89.2
7=CIGARETTE	616	0.4	148387	89.6
8=PLANT MATERIAL	66	0.0	148453	89.6
10=OTHER	21	0.0	148474	89.6
11=PIECES/CHUNKS	17172	10.4	165646	100.0

Form of CODEINE

FORM14	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-2=NO RESPONSE	9	0.0	9	0.0
-1=MISSING	97	0.1	106	0.1
0=Did not use drug	165192	99.7	165298	99.8
1=TABL/CAP/PILL	330	0.2	165628	100.0
2=AEROSOL	1	0.0	165629	100.0
3=LIQUID/ORAL	11	0.0	165640	100.0
4=POWDER	2	0.0	165642	100.0
6=LIQUID/INJECT	1	0.0	165643	100.0
11=PIECES/CHUNKS	3	0.0	165646	100.0

Form of CODEINE COMBO

FORM15	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	1	0.0	1	0.0
-2=NO RESPONSE	13	0.0	14	0.0
-1=MISSING	33	0.0	47	0.0
0=Did not use drug	164213	99.1	164260	99.2
1=TABL/CAP/PILL	1361	0.8	165621	100.0
3=LIQUID/ORAL	25	0.0	165646	100.0

Form of d-PROPOXYPHENE

FORM16	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	1	0.0	1	0.0
-2=NO RESPONSE	8	0.0	9	0.0
-1=MISSING	66	0.0	75	0.0
0=Did not use drug	164564	99.3	164639	99.4
1=TABL/CAP/PILL	1007	0.6	165646	100.0

Form of DESIPRAMINE

FORM17	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	1	0.0	1	0.0
-2=NO RESPONSE	7	0.0	8	0.0
-1=MISSING	8	0.0	16	0.0
0=Did not use drug	165424	99.9	165440	99.9
1=TABL/CAP/PILL	204	0.1	165644	100.0
8=PLANT MATERIAL	1	0.0	165645	100.0
10=OTHER	1	0.0	165646	100.0

Form of DIAZEPAM

FORM18	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	1	0.0	1	0.0
-2=NO RESPONSE	27	0.0	28	0.0
-1=MISSING	208	0.1	236	0.1
0=Did not use drug	162538	98.1	162774	98.3
1=TABL/CAP/PILL	2855	1.7	165629	100.0
2=AEROSOL	2	0.0	165631	100.0
3=LIQUID/ORAL	5	0.0	165636	100.0
4=POWDER	2	0.0	165638	100.0
6=LIQUID/INJECT	7	0.0	165645	100.0
7=CIGARETTE	1	0.0	165646	100.0

Form of DIPHENHYDRAMINE

FORM19	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	1	0.0	1	0.0
-2=NO RESPONSE	26	0.0	27	0.0
-1=MISSING	176	0.1	203	0.1
0=Did not use drug	163642	98.8	163845	98.9
1=TABL/CAP/PILL	1767	1.1	165612	100.0
3=LIQUID/ORAL	32	0.0	165644	100.0
6=LIQUID/INJECT	1	0.0	165645	100.0
10=OTHER	1	0.0	165646	100.0

Form of DIPHENYLHYDANTOIN SODIUM

FORM20	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-2=NO RESPONSE	4	0.0	4	0.0
-1=MISSING	30	0.0	34	0.0
0=Did not use drug	164708	99.4	164742	99.5
1=TABL/CAP/PILL	901	0.5	165643	100.0
2=AEROSOL	1	0.0	165644	100.0
3=LIQUID/ORAL	2	0.0	165646	100.0

Form of DOXEPIN

FORM21	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-2=NO RESPONSE	2	0.0	2	0.0
-1=MISSING	26	0.0	28	0.0
0=Did not use drug	165025	99.6	165053	99.6
1=TABL/CAP/PILL	593	0.4	165646	100.0

Form of ETHCHLORVYNOL

FORM22	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-2=NO RESPONSE	2	0.0	2	0.0
-1=MISSING	2	0.0	4	0.0
0=Did not use drug	165591	100	165595	100.0
1=TABL/CAP/PILL	50	0.0	165645	100.0
4=POWDER	1	0.0	165646	100.0

Form of FLUOXETINE

FORM23	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	1	0.0	1	0.0
-2=NO RESPONSE	21	0.0	22	0.0
-1=MISSING	36	0.0	58	0.0
0=Did not use drug	163863	98.9	163921	99.0
1=TABL/CAP/PILL	1725	1.0	165646	100.0

Form of FLURAZEPAM

FORM24	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-2=NO RESPONSE	2	0.0	2	0.0
-1=MISSING	17	0.0	19	0.0
0=Did not use drug	165334	99.8	165353	99.8
1=TABL/CAP/PILL	293	0.2	165646	100.0

Form of GLUTETHIMIDE

FORM25	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use drug	165643	100.0	165643	100.0
1=TABL/CAP/PILL	3	0.0	165646	100.0

Form of HALOPERIDOL

FORM26	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-2=NO RESPONSE	11	0.0	11	0.0
-1=MISSING	36	0.0	47	0.0
0=Did not use drug	164722	99.4	164769	99.5
1=TABL/CAP/PILL	873	0.5	165642	100.0
2=AEROSOL	1	0.0	165643	100.0
3=LIQUID/ORAL	3	0.0	165646	100.0

Form of HEROIN/MORPHINE

FORM27	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	52	0.0	52	0.0
-2=NO RESPONSE	130	0.1	182	0.1
-1=MISSING	14889	9.0	15071	9.1
0=Did not use drug	132742	80.1	147813	89.2
1=TABL/CAP/PILL	124	0.1	147937	89.3
2=AEROSOL	2	0.0	147939	89.3
3=LIQUID/ORAL	80	0.0	148019	89.4
4=POWDER	12240	7.4	160259	96.7
5=PAPER	22	0.0	160281	96.8
6=LIQUID/INJECT	4706	2.8	164987	99.6
7=CIGARETTE	40	0.0	165027	99.6
8=PLANT MATERIAL	37	0.0	165064	99.6
10=OTHER	29	0.0	165093	99.7
11=PIECES/CHUNKS	553	0.3	165646	100.0

Form of HYDROMORPHONE

FORM28	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-1=MISSING	39	0.0	39	0.0
0=Did not use drug	165525	99.9	165564	100.0
1=TABL/CAP/PILL	66	0.0	165630	100.0
6=LIQUID/INJECT	16	0.0	165646	100.0

Form of IMIPRAMINE

FORM29	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-2=NO RESPONSE	1	0.0	1	0.0
-1=MISSING	30	0.0	31	0.0
0=Did not use drug	165229	99.7	165260	99.8
1=TABL/CAP/PILL	386	0.2	165646	100.0

Form of INHALENT/SOLVENT/AEROSOL

FORM30	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	4	0.0	4	0.0
-2=NO RESPONSE	3	0.0	7	0.0
-1=MISSING	84	0.1	91	0.1
0=Did not use drug	165298	99.8	165389	99.8
1=TABL/CAP/PILL	7	0.0	165396	99.8
2=AEROSOL	142	0.1	165538	99.9
3=LIQUID/ORAL	61	0.0	165599	100.0
4=POWDER	1	0.0	165600	100.0
6=LIQUID/INJECT	4	0.0	165604	100.0
8=PLANT MATERIAL	1	0.0	165605	100.0
10=OTHER	41	0.0	165646	100.0

Form of LORAZEPAM

FORM31	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	2	0.0	2	0.0
-2=NO RESPONSE	11	0.0	13	0.0
-1=MISSING	57	0.0	70	0.0
0=Did not use drug	163939	99.0	164009	99.0
1=TABL/CAP/PILL	1634	1.0	165643	100.0
2=AEROSOL	2	0.0	165645	100.0
4=POWDER	1	0.0	165646	100.0

Form of LSD

FORM32	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-2=NO RESPONSE	18	0.0	18	0.0
-1=MISSING	775	0.5	793	0.5
0=Did not use drug	164185	99.1	164978	99.6
1=TABL/CAP/PILL	92	0.1	165070	99.7
2=AEROSOL	1	0.0	165071	99.7
3=LIQUID/ORAL	20	0.0	165091	99.7
4=POWDER	20	0.0	165111	99.7
5=PAPER	496	0.3	165607	100.0
6=LIQUID/INJECT	5	0.0	165612	100.0
7=CIGARETTE	9	0.0	165621	100.0
8=PLANT MATERIAL	10	0.0	165631	100.0
10=OTHER	9	0.0	165640	100.0
11=PIECES/CHUNKS	6	0.0	165646	100.0

Form of MARIJUANA/HASHISH

FORM33	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	9	0.0	9	0.0
-2=NO RESPONSE	162	0.1	171	0.1
-1=MISSING	7014	4.2	7185	4.3
0=Did not use drug	149301	90.1	156486	94.5
1=TABL/CAP/PILL	50	0.0	156536	94.5
2=AEROSOL	1	0.0	156537	94.5
3=LIQUID/ORAL	3	0.0	156540	94.5
4=POWDER	47	0.0	156587	94.5
5=PAPER	11	0.0	156598	94.5
6=LIQUID/INJECT	26	0.0	156624	94.6
7=CIGARETTE	3972	2.4	160596	97.0
8=PLANT MATERIAL	4930	3.0	165526	99.9
10=OTHER	10	0.0	165536	99.9
11=PIECES/CHUNKS	110	0.1	165646	100.0

Form of MEPERIDINE HCL

FORM34	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-1=MISSING	31	0.0	31	0.0
0=Did not use drug	165451	99.9	165482	99.9
1=TABL/CAP/PILL	118	0.1	165600	100.0
2=AEROSOL	1	0.0	165601	100.0
3=LIQUID/ORAL	1	0.0	165602	100.0
6=LIQUID/INJECT	44	0.0	165646	100.0

Form of MEPROBAMATE

FORM35	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-1=MISSING	19	0.0	19	0.0
0=Did not use drug	165544	99.9	165563	99.9
1=TABL/CAP/PILL	83	0.1	165646	100.0

Form of METHADONE

FORM36	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-2=NO RESPONSE	30	0.0	30	0.0
-1=MISSING	565	0.3	595	0.4
0=Did not use drug	164066	99.0	164661	99.4
1=TABL/CAP/PILL	344	0.2	165005	99.6
2=AEROSOL	6	0.0	165011	99.6
3=LIQUID/ORAL	574	0.3	165585	100.0
4=POWDER	37	0.0	165622	100.0
5=PAPER	1	0.0	165623	100.0
6=LIQUID/INJECT	16	0.0	165639	100.0
8=PLANT MATERIAL	3	0.0	165642	100.0
10=OTHER	3	0.0	165645	100.0
11=PIECES/CHUNKS	1	0.0	165646	100.0

Form of METHAMPHETAMINE

FORM37	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	20	0.0	20	0.0
-2=NO RESPONSE	15	0.0	35	0.0
-1=MISSING	1752	1.1	1787	1.1
0=Did not use drug	161787	97.7	163574	98.7
1=TABL/CAP/PILL	151	0.1	163725	98.8
3=LIQUID/ORAL	8	0.0	163733	98.8
4=POWDER	1532	0.9	165265	99.8
5=PAPER	6	0.0	165271	99.8
6=LIQUID/INJECT	207	0.1	165478	99.9
7=CIGARETTE	23	0.0	165501	99.9
8=PLANT MATERIAL	9	0.0	165510	99.9
10=OTHER	4	0.0	165514	99.9
11=PIECES/CHUNKS	132	0.1	165646	100.0

Form of METHAQUALONE

FORM38	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-1=MISSING	11	0.0	11	0.0
0=Did not use drug	165530	99.9	165541	99.9
1=TABL/CAP/PILL	105	0.1	165646	100.0

Form of METHYLPHENIDATE

FORM39	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-2=NO RESPONSE	1	0.0	1	0.0
-1=MISSING	7	0.0	8	0.0
0=Did not use drug	165438	99.9	165446	99.9
1=TABL/CAP/PILL	195	0.1	165641	100.0
6=LIQUID/INJECT	5	0.0	165646	100.0

Form of OVER THE COUNTER DIET AIDS

FORM40	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	1	0.0	1	0.0
-1=MISSING	8	0.0	9	0.0
0=Did not use drug	165373	99.8	165382	99.8
1=TABL/CAP/PILL	264	0.2	165646	100.0

Form of OVER THE COUNTER SLEEP AIDS

FORM41	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	2	0.0	2	0.0
-2=NO RESPONSE	6	0.0	8	0.0
-1=MISSING	37	0.0	45	0.0
0=Did not use drug	164506	99.3	164551	99.3
1=TABL/CAP/PILL	1075	0.6	165626	100.0
3=LIQUID/ORAL	20	0.0	165646	100.0

Form of OXYCODONE

FORM42	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	1	0.0	1	0.0
-2=NO RESPONSE	7	0.0	8	0.0
-1=MISSING	47	0.0	55	0.0
0=Did not use drug	164760	99.5	164815	99.5
1=TABL/CAP/PILL	831	0.5	165646	100.0

Form of PCP/PCP COMBO

FORM43	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	2	0.0	2	0.0
-2=NO RESPONSE	35	0.0	37	0.0
-1=MISSING	2105	1.3	2142	1.3
0=Did not use drug	162119	97.9	164261	99.2
1=TABL/CAP/PILL	83	0.1	164344	99.2
3=LIQUID/ORAL	12	0.0	164356	99.2
4=POWDER	385	0.2	164741	99.5
5=PAPER	20	0.0	164761	99.5
6=LIQUID/INJECT	17	0.0	164778	99.5
7=CIGARETTE	687	0.4	165465	99.9
8=PLANT MATERIAL	130	0.1	165595	100.0
10=OTHER	11	0.0	165606	100.0
11=PIECES/CHUNKS	40	0.0	165646	100.0

Form of PENTAZOCINE

FORM44	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-2=NO RESPONSE	2	0.0	2	0.0
-1=MISSING	4	0.0	6	0.0
0=Did not use drug	165595	100.0	165601	100.0
1=TABL/CAP/PILL	45	0.0	165646	100.0

Form of PENTOBARBITAL

FORM45	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-1=MISSING	1	0.0	1	0.0
0=Did not use drug	165623	100.0	165624	100.0
1=TABL/CAP/PILL	20	0.0	165644	100.0
6=LIQUID/INJECT	1	0.0	165645	100.0
10=OTHER	1	0.0	165646	100.0

Form of PHENOBARBITAL

FORM46	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-2=NO RESPONSE	5	0.0	5	0.0
-1=MISSING	31	0.0	36	0.0
0=Did not use drug	165016	99.6	165052	99.6
1=TABL/CAP/PILL	590	0.4	165642	100.0
2=AEROSOL	2	0.0	165644	100.0
3=LIQUID/ORAL	1	0.0	165645	100.0
6=LIQUID/INJECT	1	0.0	165646	100.0

Form of SECOBARBITAL

FORM47	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	1	0.0	1	0.0
-1=MISSING	3	0.0	4	0.0
0=Did not use drug	165597	100	165601	100.0
1=TABL/CAP/PILL	45	0.0	165646	100.0

Form of SECOBARBTL/AMOBARBITAL

FORM48	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-1=MISSING	3	0.0	3	0.0
0=Did not use drug	165638	100.0	165641	100.0
1=TABL/CAP/PILL	5	0.0	165646	100.0

Form of THIORIDAZINE

FORM49	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	1	0.0	1	0.0
-2=NO RESPONSE	6	0.0	7	0.0
-1=MISSING	22	0.0	29	0.0
0=Did not use drug	165114	99.7	165143	99.7
1=TABL/CAP/PILL	498	0.3	165641	100.0
2=AEROSOL	3	0.0	165644	100.0
3=LIQUID/ORAL	1	0.0	165645	100.0
6=LIQUID/INJECT	1	0.0	165646	100.0

Form of TRIFLUOPERAZINE

FORM50	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-2=NO RESPONSE	1	0.0	1	0.0
-1=MISSING	4	0.0	5	0.0
0=Did not use drug	165451	99.9	165456	99.9
1=TABL/CAP/PILL	190	0.1	165646	100.0

Form of DRUGS in OTHER CATEGORY

FORM51	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	966	0.6	966	0.6
-2=NO RESPONSE	241	0.1	1207	0.7
-1=MISSING	6137	3.7	7344	4.4
0=Did not use drug	131420	79.3	138764	83.8
1=TABL/CAP/PILL	25709	15.5	164473	99.3
2=AEROSOL	39	0.0	164512	99.3
3=LIQUID/ORAL	392	0.2	164904	99.6
4=POWDER	150	0.1	165054	99.6
5=PAPER	3	0.0	165057	99.6
6=LIQUID/INJECT	334	0.2	165391	99.8
7=CIGARETTE	23	0.0	165414	99.9
8=PLANT MATERIAL	196	0.1	165610	100.0
10=OTHER	21	0.0	165631	100.0
11=PIECES/CHUNKS	15	0.0	165646	100.0

Form of DRUGS, UNKNOWN

FORM52	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	51	0.0	51	0.0
-2=NO RESPONSE	33	0.0	84	0.1
-1=MISSING	11155	6.7	11239	6.8
0=Did not use drug	150566	90.9	161805	97.7
1=TABL/CAP/PILL	1773	1.1	163578	98.8
2=AEROSOL	8	0.0	163586	98.8
3=LIQUID/ORAL	35	0.0	163621	98.8
4=POWDER	237	0.1	163858	98.9
5=PAPER	3	0.0	163861	98.9
6=LIQUID/INJECT	1700	1.0	165561	99.9
7=CIGARETTE	25	0.0	165586	100.0
8=PLANT MATERIAL	26	0.0	165612	100.0
10=OTHER	12	0.0	165624	100.0
11=PIECES/CHUNKS	22	0.0	165646	100.0

DRUG USE MOTIVE

MOTIVE	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-1=MISSING	22297	13.5	22297	13.5
2=DEPENDENCE	78436	47.4	100733	60.8
3=SUICIDE	39866	24.1	140599	84.9
5=OTHER	958	0.6	141557	85.5
6=RECREATIONAL USE	14411	8.7	155968	94.2
7=PSYCHO EFFECTS	9678	5.8	165646	100.0

PATIENT RACE/ETHNICITY

RACE	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-1=MISSING	13906	8.4	13906	8.4
1=WHITE	56616	34.2	70522	42.6
2=BLACK	75014	45.3	145536	87.9
3=HISPANIC	18254	11.0	163790	98.9
4=AMER IND/ALASKN	257	0.2	164047	99.0
5=OTHER	1599	1.0	165646	100.0

REASON FOR ER VISIT

REASON	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-2=NO RESPONSE	2687	1.6	2687	1.6
-1=MISSING	5103	3.1	7790	4.7
1=UNEXPECTD REACTN	29935	18.1	37725	22.8
2=OVERDOSE	55252	33.4	92977	56.1
3=WITHDRAWL	4885	2.9	97862	59.1
4=CHRONIC EFFECTS	33045	19.9	130907	79.0
6=OTHER	8070	4.9	138977	83.9
7=SEEKING DETOXFTN	17922	10.8	156899	94.7
8=ACCIDENT/INJURY	8747	5.3	165646	100.0

Route for ACETAMINOPHEN

ROUTE01	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	3	0.0	3	0.0
-2=NO RESPONSE	55	0.0	58	0.0
-1=MISSING	267	0.2	325	0.2
0=Did not use drug	158168	95.5	158493	95.7
1=ORAL	7137	4.3	165630	100.0
2=INJECTED	10	0.0	165640	100.0
4=SMOKE	4	0.0	165644	100.0
5=SNIFF/SNORT	1	0.0	165645	100.0
7=OTHER	1	0.0	165646	100.0

Route for ALCOHOL-IN-COMBO

ROUTE02	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use drug	107568	64.9	107568	64.9
1=ORAL	58078	35.1	165646	100.0

Route for ALPRAZOLAM

ROUTE03	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-2=NO RESPONSE	19	0.0	19	0.0
-1=MISSING	152	0.1	171	0.1
0=Did not use drug	162602	98.2	162773	98.3
1=ORAL	2861	1.7	165634	100.0
2=INJECTED	11	0.0	165645	100.0
4=SMOKE	1	0.0	165646	100.0

Route for AMITRIPTYLINE

ROUTE04	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	1	0.0	1	0.0
-2=NO RESPONSE	14	0.0	15	0.0
-1=MISSING	57	0.0	72	0.0
0=Did not use drug	164012	99.0	164084	99.1
1=ORAL	1560	0.9	165644	100.0
2=INJECTED	1	0.0	165645	100.0
5=SNIFF/SNORT	1	0.0	165646	100.0

Route for AMITRIPTYLN COMB

ROUTE05	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-2=NO RESPONSE	3	0.0	3	0.0
-1=MISSING	6	0.0	9	0.0
0=Did not use drug	165550	99.9	165559	99.9
1=ORAL	87	0.1	165646	100.0

Route for AMPHETAMINE

ROUTE06	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	5	0.0	5	0.0
-2=NO RESPONSE	28	0.0	33	0.0
-1=MISSING	1183	0.7	1216	0.7
0=Did not use drug	163354	98.6	164570	99.4
1=ORAL	601	0.4	165171	99.7
2=INJECTED	258	0.2	165429	99.9
3=INHALE	7	0.0	165436	99.9
4=SMOKE	46	0.0	165482	99.9
5=SNIFF/SNORT	163	0.1	165645	100.0
7=OTHER	1	0.0	165646	100.0

Route for ASPIRIN

ROUTE07	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	2	0.0	2	0.0
-2=NO RESPONSE	25	0.0	27	0.0
-1=MISSING	130	0.1	157	0.1
0=Did not use drug	161957	97.8	162114	97.9
1=ORAL	3522	2.1	165636	100.0
2=INJECTED	5	0.0	165641	100.0
3=INHALE	1	0.0	165642	100.0
4=SMOKE	2	0.0	165644	100.0
7=OTHER	2	0.0	165646	100.0

Route for BUTALBITAL COMBO

ROUTE08	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	1	0.0	1	0.0
-2=NO RESPONSE	4	0.0	5	0.0
-1=MISSING	11	0.0	16	0.0
0=Did not use drug	165314	99.8	165330	99.8
1=ORAL	316	0.2	165646	100.0

50

Route for CHLORAL HYDRATE

ROUTE09	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-2=NO RESPONSE	1	0.0	1	0.0
-1=MISSING	2	0.0	3	0.0
0=Did not use drug	165546	99.9	165549	99.9
1=ORAL	95	0.1	165644	100.0
2=INJECTED	2	0.0	165646	100.0

Route for CHLORDIAZEPOXIDE

ROUTE10	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	1	0.0	1	0.0
-2=NO RESPONSE	7	0.0	8	0.0
-1=MISSING	28	0.0	36	0.0
0=Did not use drug	165188	99.7	165224	99.7
1=ORAL	422	0.3	165646	100.0

Route for CHLORPROMAZINE

ROUTE11	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-2=NO RESPONSE	5	0.0	5	0.0
-1=MISSING	19	0.0	24	0.0
0=Did not use drug	165155	99.7	165179	99.7
1=ORAL	465	0.3	165644	100.0
5=SNIFF/SNORT	2	0.0	165646	100.0

Route for CLORAZEPATE

ROUTE12	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-2=NO RESPONSE	2	0.0	2	0.0
-1=MISSING	11	0.0	13	0.0
0=Did not use drug	165480	99.9	165493	99.9
1=ORAL	152	0.1	165645	100.0
2=INJECTED	1	0.0	165646	100.0

Route for COCAINE

ROUTE13	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	1349	0.8	1349	0.8
-2=NO RESPONSE	304	0.2	1653	1.0
-1=MISSING	25247	15.2	26900	16.2
0=Did not use drug	96760	58.4	123660	74.7
1=ORAL	330	0.2	123990	74.9
2=INJECTED	10923	6.6	134913	81.4
3=INHALE	410	0.2	135323	81.7
4=SMOKE	23804	14.4	159127	96.1
5=SNIFF/SNORT	6482	3.9	165609	100.0
7=OTHER	37	0.0	165646	100.0

Route for CODEINE

ROUTE14	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-2=NO RESPONSE	11	0.0	11	0.0
-1=MISSING	86	0.1	97	0.1
0=Did not use drug	165192	99.7	165289	99.8
1=ORAL	349	0.2	165638	100.0
2=INJECTED	3	0.0	165641	100.0
4=SMOKE	3	0.0	165644	100.0
5=SNIFF/SNORT	2	0.0	165646	100.0

Route for CODEINE COMBO

ROUTE15	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	1	0.0	1	0.0
-2=NO RESPONSE	14	0.0	15	0.0
-1=MISSING	31	0.0	46	0.0
0=Did not use drug	164213	99.1	164259	99.2
1=ORAL	1386	0.8	165645	100.0
2=INJECTED	1	0.0	165646	100.0

Route for d-PROPOXYPHENE

ROUTE16	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	1	0.0	1	0.0
-2=NO RESPONSE	7	0.0	8	0.0
-1=MISSING	65	0.0	73	0.0
0=Did not use drug	164564	99.3	164637	99.4
1=ORAL	1007	0.6	165644	100.0
2=INJECTED	1	0.0	165645	100.0
4=SMOKE	1	0.0	165646	100.0

Route for DESIPRAMINE

ROUTE17	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-2=NO RESPONSE	8	0.0	8	0.0
-1=MISSING	10	0.0	18	0.0
0=Did not use drug	165424	99.9	165442	99.9
1=ORAL	203	0.1	165645	100.0
7=OTHER	1	0.0	165646	100.0

Route for DIAZEPAM

ROUTE18	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	1	0.0	1	0.0
-2=NO RESPONSE	28	0.0	29	0.0
-1=MISSING	199	0.1	228	0.1
0=Did not use drug	162538	98.1	162766	98.3
1=ORAL	2863	1.7	165629	100.0
2=INJECTED	14	0.0	165643	100.0
4=SMOKE	1	0.0	165644	100.0
5=SNIFF/SNORT	2	0.0	165646	100.0

Route for DIPHENHYDRAMINE

ROUTE19	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	1	0.0	1	0.0
-2=NO RESPONSE	24	0.0	25	0.0
-1=MISSING	151	0.1	176	0.1
0=Did not use drug	163642	98.8	163818	98.9
1=ORAL	1823	1.1	165641	100.0
2=INJECTED	4	0.0	165645	100.0
3=INHALE	1	0.0	165646	100.0

Route for DIPHENYLHYDANTOIN SODIUM

ROUTE20	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-2=NO RESPONSE	4	0.0	4	0.0
-1=MISSING	27	0.0	31	0.0
0=Did not use drug	164708	99.4	164739	99.5
1=ORAL	904	0.5	165643	100.0
2=INJECTED	2	0.0	165645	100.0
7=OTHER	1	0.0	165646	100.0

Route for DOXEPIN

ROUTE21	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-2=NO RESPONSE	3	0.0	3	0.0
-1=MISSING	23	0.0	26	0.0
0=Did not use drug	165025	99.6	165051	99.6
1=ORAL	595	0.4	165646	100.0

Route for ETHCHLORVYNOL

ROUTE22	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-2=NO RESPONSE	2	0.0	2	0.0
-1=MISSING	1	0.0	3	0.0
0=Did not use drug	165591	100.0	165594	100.0
1=ORAL	51	0.0	165645	100.0
2=INJECTED	1	0.0	165646	100.0

Route for FLUOXETINE

ROUTE23	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	1	0.0	1	0.0
-2=NO RESPONSE	22	0.0	23	0.0
-1=MISSING	33	0.0	56	0.0
0=Did not use drug	163863	98.9	163919	99.0
1=ORAL	1723	1.0	165642	100.0
2=INJECTED	2	0.0	165644	100.0
5=SNIFF/SNORT	2	0.0	165646	100.0

Route for FLURAZEPAM

ROUTE24	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-2=NO RESPONSE	2	0.0	2	0.0
-1=MISSING	15	0.0	17	0.0
0=Did not use drug	165334	99.8	165351	99.8
1=ORAL	295	0.2	165646	100.0

Route for GLUTETHIMIDE

ROUTE25	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0=Did not use drug	165643	100.0	165643	100.0
1=ORAL	3	0.0	165646	100.0

Route for HALOPERIDOL

ROUTE26	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-2=NO RESPONSE	10	0.0	10	0.0
-1=MISSING	32	0.0	42	0.0
0=Did not use drug	164722	99.4	164764	99.5
1=ORAL	879	0.5	165643	100.0
2=INJECTED	2	0.0	165645	100.0
5=SNIFF/SNORT	1	0.0	165646	100.0

Route for HEROIN/MORPHINE

ROUTE27	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	153	0.1	153	0.1
-2=NO RESPONSE	142	0.1	295	0.2
-1=MISSING	7950	4.8	8245	5.0
0=Did not use drug	132742	80.1	140987	85.1
1=ORAL	179	0.1	141166	85.2
2=INJECTED	20235	12.2	161401	97.4
3=INHALE	102	0.1	161503	97.5
4=SMOKE	533	0.3	162036	97.8
5=SNIFF/SNORT	3589	2.2	165625	100.0
7=OTHER	21	0.0	165646	100.0

Route for HYDROMORPHONE

ROUTE28	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-1=MISSING	28	0.0	28	0.0
0=Did not use drug	165525	99.9	165553	99.9
1=ORAL	59	0.0	165612	100.0
2=INJECTED	34	0.0	165646	100.0

Route for IMIPRAMINE

ROUTE29	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-2=NO RESPONSE	1	0.0	1	0.0
-1=MISSING	30	0.0	31	0.0
0=Did not use drug	165229	99.7	165260	99.8
1=ORAL	386	0.2	165646	100.0

Route for INHALENT/SOLVENT/AEROSOL

ROUTE30	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	4	0.0	4	0.0
-2=NO RESPONSE	3	0.0	7	0.0
-1=MISSING	16	0.0	23	0.0
0=Did not use drug	165298	99.8	165321	99.8
1=ORAL	47	0.0	165368	99.8
2=INJECTED	6	0.0	165374	99.8
3=INHALE	185	0.1	165559	99.9
4=SMOKE	2	0.0	165561	99.9
5=SNIFF/SNORT	84	0.1	165645	100.0
7=OTHER	1	0.0	165646	100.0

Route for LORAZEPAM

ROUTE31	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	2	0.0	2	0.0
-2=NO RESPONSE	12	0.0	14	0.0
-1=MISSING	55	0.0	69	0.0
0=Did not use drug	163939	99.0	164008	99.0
1=ORAL	1633	1.0	165641	100.0
2=INJECTED	5	0.0	165646	100.0

Route for LSD

ROUTE32	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-2=NO RESPONSE	16	0.0	16	0.0
-1=MISSING	738	0.4	754	0.5
0=Did not use drug	164185	99.1	164939	99.6
1=ORAL	634	0.4	165573	100.0
2=INJECTED	19	0.0	165592	100.0
3=INHALE	2	0.0	165594	100.0
4=SMOKE	35	0.0	165629	100.0
5=SNIFF/SNORT	6	0.0	165635	100.0
7=OTHER	11	0.0	165646	100.0

Route for MARIJUANA/HASHISH

ROUTE33	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	12	0.0	12	0.0
-2=NO RESPONSE	157	0.1	169	0.1
-1=MISSING	4524	2.7	4693	2.8
0=Did not use drug	149301	90.1	153994	93.0
1=ORAL	85	0.1	154079	93.0
2=INJECTED	45	0.0	154124	93.0
3=INHALE	157	0.1	154281	93.1
4=SMOKE	11288	6.8	165569	100.0
5=SNIFF/SNORT	73	0.0	165642	100.0
7=OTHER	4	0.0	165646	100.0

Route for MEPERIDINE HCL

ROUTE34	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-1=MISSING	26	0.0	26	0.0
0=Did not use drug	165451	99.9	165477	99.9
1=ORAL	119	0.1	165596	100.0
2=INJECTED	50	0.0	165646	100.0

Route for MEPROBAMATE

ROUTE35	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-1=MISSING	19	0.0	19	0.0
0=Did not use drug	165544	99.9	165563	99.9
1=ORAL	83	0.1	165646	100.0

Route for METHADONE

ROUTE36	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-2=NO RESPONSE	30	0.0	30	0.0
-1=MISSING	434	0.3	464	0.3
0=Did not use drug	164066	99.0	164530	99.3
1=ORAL	1049	0.6	165579	100.0
2=INJECTED	54	0.0	165633	100.0
3=INHALE	1	0.0	165634	100.0
4=SMOKE	2	0.0	165636	100.0
5=SNIFF/SNORT	7	0.0	165643	100.0
7=OTHER	3	0.0	165646	100.0

Route for METHAMPHETAMINE

ROUTE37	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	50	0.0	50	0.0
-2=NO RESPONSE	17	0.0	67	0.0
-1=MISSING	1479	0.9	1546	0.9
0=Did not use drug	161787	97.7	163333	98.6
1=ORAL	219	0.1	163552	98.7
2=INJECTED	1046	0.6	164598	99.4
3=INHALE	34	0.0	164632	99.4
4=SMOKE	280	0.2	164912	99.6
5=SNIFF/SNORT	722	0.4	165634	100.0
7=OTHER	12	0.0	165646	100.0

Route for METHAQUALONE

ROUTE38	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-1=MISSING	9	0.0	9	0.0
0=Did not use drug	165530	99.9	165539	99.9
1=ORAL	107	0.1	165646	100.0

Route for METHYLPHENIDATE

ROUTE39	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-2=NO RESPONSE	1	0.0	1	0.0
-1=MISSING	6	0.0	7	0.0
0=Did not use drug	165438	99.9	165445	99.9
1=ORAL	193	0.1	165638	100.0
2=INJECTED	7	0.0	165645	100.0
5=SNIFF/SNORT	1	0.0	165646	100.0

Route for OVER THE COUNTER DIET AIDS

ROUTE40	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	1	0.0	1	0.0
-1=MISSING	8	0.0	9	0.0
0=Did not use drug	165373	99.8	165382	99.8
1=ORAL	264	0.2	165646	100.0

Route for OVER THE COUNTER SLEEP AIDS

ROUTE41	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	1	0.0	1	0.0
-2=NO RESPONSE	5	0.0	6	0.0
-1=MISSING	31	0.0	37	0.0
0=Did not use drug	164506	99.3	164543	99.3
1=ORAL	1102	0.7	165645	100.0
2=INJECTED	1	0.0	165646	100.0

Route for OXYCODONE

ROUTE42	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	1	0.0	1	0.0
-2=NO RESPONSE	7	0.0	8	0.0
-1=MISSING	46	0.0	54	0.0
0=Did not use drug	164760	99.5	164814	99.5
1=ORAL	830	0.5	165644	100.0
2=INJECTED	1	0.0	165645	100.0
5=SNIFF/SNORT	1	0.0	165646	100.0

Route for PCP/PCP COMBO

ROUTE43	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	3	0.0	3	0.0
-2=NO RESPONSE	34	0.0	37	0.0
-1=MISSING	1484	0.9	1521	0.9
0=Did not use drug	162119	97.9	163640	98.8
1=ORAL	117	0.1	163757	98.9
2=INJECTED	27	0.0	163784	98.9
3=INHALE	58	0.0	163842	98.9
4=SMOKE	1762	1.1	165604	100.0
5=SNIFF/SNORT	40	0.0	165644	100.0
7=OTHER	2	0.0	165646	100.0

Route for PENTAZOCINE

ROUTE44	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-2=NO RESPONSE	2	0.0	2	0.0
-1=MISSING	4	0.0	6	0.0
0=Did not use drug	165595	100.0	165601	100.0
1=ORAL	45	0.0	165646	100.0

Route for PENTOBARBITAL

ROUTE45	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-1=MISSING	1	0.0	1	0.0
0=Did not use drug	165623	100.0	165624	100.0
1=ORAL	20	0.0	165644	100.0
2=INJECTED	1	0.0	165645	100.0
7=OTHER	1	0.0	165646	100.0

Route for PHENOBARBITAL

ROUTE46	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-2=NO RESPONSE	4	0.0	4	0.0
-1=MISSING	32	0.0	36	0.0
0=Did not use drug	165016	99.6	165052	99.6
1=ORAL	592	0.4	165644	100.0
2=INJECTED	2	0.0	165646	100.0

Route for SECOBARBITAL

ROUTE47	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	1	0.0	1	0.0
-1=MISSING	3	0.0	4	0.0
0=Did not use drug	165597	100	165601	100.0
1=ORAL	45	0.0	165646	100.0

Route for SECOBARBTL/AMOBARBITAL

ROUTE48	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-1=MISSING	1	0.0	1	0.0
0=Did not use drug	165638	100.0	165639	100.0
1=ORAL	7	0.0	165646	100.0

Route for THIORIDAZINE

ROUTE49	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	1	0.0	1	0.0
-2=NO RESPONSE	6	0.0	7	0.0
-1=MISSING	14	0.0	21	0.0
0=Did not use drug	165114	99.7	165135	99.7
1=ORAL	509	0.3	165644	100.0
2=INJECTED	1	0.0	165645	100.0
3=INHALE	1	0.0	165646	100.0

Route for TRIFLUOPERAZINE

ROUTE50	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-2=NO RESPONSE	1	0.0	1	0.0
-1=MISSING	3	0.0	4	0.0
0=Did not use drug	165451	99.9	165455	99.9
1=ORAL	191	0.1	165646	100.0

Route for DRUGS in OTHER CATEGORY

ROUTE51	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	777	0.5	777	0.5
-2=NO RESPONSE	239	0.1	1016	0.6
-1=MISSING	5522	3.3	6538	3.9
0=Did not use drug	131420	79.3	137958	83.3
1=ORAL	26621	16.1	164579	99.4
2=INJECTED	814	0.5	165393	99.8
3=INHALE	22	0.0	165415	99.9
4=SMOKE	78	0.0	165493	99.9
5=SNIFF/SNORT	128	0.1	165621	100.0
7=OTHER	25	0.0	165646	100.0

Route for DRUGS, UNKNOWN

ROUTE52	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-3=MULT RESPONSE	47	0.0	47	0.0
-2=NO RESPONSE	32	0.0	79	0.0
-1=MISSING	3870	2.3	3949	2.4
0=Did not use drug	150566	90.9	154515	93.3
1=ORAL	1844	1.1	156359	94.4
2=INJECTED	9118	5.5	165477	99.9
3=INHALE	19	0.0	165496	99.9
4=SMOKE	105	0.1	165601	100.0
5=SNIFF/SNORT	38	0.0	165639	100.0
7=OTHER	7	0.0	165646	100.0

SEX OF PATIENT

SEX	Frequency	Percent	Cumulative Frequency	Cumulative Percent
-1=MISSING	1759	1.1	1759	1.1
1=MALE	97549	58.9	99308	60.0
2=FEMALE	66338	40.0	165646	100.0

MODIFIED STRATUM

STRATUM	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0	51709	31.2	51709	31.2
1	76060	45.9	127769	77.1
2	33619	20.3	161388	97.4
3	504	0.3	161892	97.7
4	1971	1.2	163863	98.9
5	1783	1.1	165646	100.0

TOTAL MENTIONS IN EPISODE (W/ DUPS)

TOTMENS	Frequency	Percent	Cumulative Frequency	Cumulative Percent
1	77446	46.8	77446	46.8
2	62222	37.6	139668	84.3
3	18801	11.4	158469	95.7
4	5773	3.5	164242	99.2
5	1404	0.8	165646	100.0

UNIQUE MENTIONS IN EPISODE (S/ DUPS)

UNIQMENS	Frequency	Percent	Cumulative Frequency	Cumulative Percent
1	78705	47.5	78705	47.5
2	62341	37.6	141046	85.1
3	18336	11.1	159382	96.2
4	5093	3.1	164475	99.3
5	1171	0.7	165646	100.0

YEAR EPISODE OCCURRED

YEAR	Frequency	Percent	Cumulative Frequency	Cumulative Percent
94	165646	100.0	165646	100.0